Association of Glucosamine and/or Chondroitin Use with Reports of  Improved Health and Joint Pain among Individuals with Arthritis, National Health Interview Survey (NHIS) 2012 by Woodard, Kedra
Georgia State University
ScholarWorks @ Georgia State University
Public Health Theses School of Public Health
Summer 8-11-2015
Association of Glucosamine and/or Chondroitin
Use with Reports of Improved Health and Joint
Pain among Individuals with Arthritis, National
Health Interview Survey (NHIS) 2012
Kedra Woodard
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Public Health Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.
Recommended Citation
Woodard, Kedra, "Association of Glucosamine and/or Chondroitin Use with Reports of Improved Health and Joint Pain among
Individuals with Arthritis, National Health Interview Survey (NHIS) 2012." Thesis, Georgia State University, 2015.
https://scholarworks.gsu.edu/iph_theses/415
Association of Glucosamine and/or Chondroitin Use with Reports of  
Improved Health and Joint Pain among Individuals with Arthritis, 
National Health Interview Survey (NHIS) 2012 
 
 
 
 
Kedra Woodard 
B.S., Anthropology and Human Biology 
Emory University, 2013 
 
 
 
 
A Thesis Submitted to the Graduate Faculty 
 of Georgia State University in Partial Fulfillment 
 of the Requirements for the Degree 
 
 
 
 
MASTER OF PUBLIC HEALTH 
GEORGIA STATE UNIVERSITY 
ATLANTA, GEORGIA 30303 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
BACKGROUND: Arthritis is increasingly becoming a public health concern as it is the leading 
cause of disability. Glucosamine and chondroitin, which are alternative dietary supplements, are 
commonly marketed for persons with joint pain. The purpose of this study is to examine if self-
reported 12-month and past 30-day use of glucosamine and/or chondroitin among persons with 
any arthritis, unspecified arthritis, and rheumatoid arthritis is associated with reports of past 12 
month improved health and reports of past 30-day joint pain, aching, and stiffness, respectively. 
 
METHODS: The 2012 National Health Interview Survey (NHIS), a nationally representative 
cross-sectional household interview survey, was used for this study. The adult sample consisted 
of 34,525. Subgroup analyses were conducted on 7,654 respondents with any arthritis, 6,016 
with unspecified arthritis, and 898 with rheumatoid arthritis. The independent variables were 
defined as the use of glucosamine only, chondroitin only, or glucosamine and chondroitin one or 
more times in the past 12 months and past 30 days. The dependent variables were defined as self-
reported past 12 month improved health and past 30 day pain, aching, and stiffness. Descriptive, 
bivariate, and multivariate analyses were conducted using SAS 9.4 accounting for the complex 
survey design, computing missing values as missing completely at random for variance 
estimation. All multivariate logistic regression models included sociodemographics, use of other 
alternative therapies, and any other chronic conditions. 
 
RESULTS: Approximately 21.8% of U.S adults had any arthritis, 17.0% had unspecified 
arthritis and 2.5% had rheumatoid arthritis. Among persons with any arthritis, approximately 
3.7% used glucosamine, 0.4% used chondroitin, and 3.4% used both glucosamine and 
chondroitin within the past 12 months while approximately 5.1% used glucosamine, 0.6% used 
chondroitin, and 0.4% used both glucosamine and chondroitin within the past 30 days. Among 
persons with unspecified arthritis, approximately 3.7% used glucosamine, 0.5% used 
chondroitin, and 3.8% used both glucosamine and chondroitin within the past 12 months while 
5.5% used glucosamine, 0.5% used chondroitin, and 0.4% used both glucosamine and 
chondroitin within the past 30 days. Among persons with rheumatoid arthritis, approximately 
2.4% used glucosamine, 0.3% used chondroitin, and 2.1% used both glucosamine and 
chondroitin within the past 12 months while approximately 2.9% used glucosamine, 0.7% used 
chondroitin, and 0.5% used both glucosamine and chondroitin within the past 30 days. Women 
used more of all supplements (past 12 months and past 30 days) except past 12 month use of 
chondroitin among persons with any arthritis. Persons 56 to 70 years old had the highest 
proportion of past 12 month and 30 day supplement use among persons with unspecified 
arthritis.  
After adjusting for sex, age, race, BMI, poverty level, other health conditions, and other CAM 
therapies (acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), the use of 
chondroitin only (adjusted OR= 0.6; p= <0.01) and the use of both glucosamine and chondroitin 
(adjusted OR= 5.7; p= <0.01) during the past 30 days was associated with self-reported past 30 
day joint pain, aching, and stiffness among persons with any arthritis. After adjusting for age, 
BMI, poverty level, region, other health conditions, and other CAM therapies (acupuncture, 
energy, mind-body, and chiropractic/osteopathic therapies), the use of chondroitin only was also 
associated with past 30 day joint pain, aching, and stiffness among persons with unspecified 
arthritis (adjusted OR= 0.5; p= 0.02).  
 
CONCLUSION: Chondroitin alone was associated reports of past 30 day joint pain, aching, and 
stiffness among persons with any arthritis and unspecified arthritis highlighting a potential 
effective role and use for this supplement. In addition, the use of both glucosamine and 
chondroitin were associated with reports of past 30 day joint pain, aching, and stiffness among 
persons with any arthritis. Marketing may play a role in these relationships and should be further 
examined.  
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CHAPTER I 
INTRODUCTION 
BACKGROUND 
Arthritis is the inflammation of one or more joints, and includes several rheumatic 
diseases and conditions. Arthritis is a disease that naturally worsens with age. Because the 
workforce in the United States is aging, arthritis is increasingly becoming a public health issue. 
In 2003, an estimated $128 billion in medical-care costs and lost earnings were due to arthritis 
alone in the United States (CDC 2007). This estimate has only increased over the years.  
Osteoarthritis and rheumatoid arthritis are the two most common forms of arthritis. 
Osteoarthritis is characterized by progressive degeneration of articular cartilage (Gibson et al. 
2014). Rheumatoid arthritis is a chronic inflammatory disease that results in damage to bone and 
cartilage (Md Yusof & Emery 2013). Current treatment for these conditions mostly consists of 
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Unfortunately, long-term use of 
these treatments could potentially cause serious adverse gastrointestinal and cardiovascular 
events (Wu et al. 2013). Using complementary and alternative medicine (CAM) therapies instead 
of, or in combination with, these treatments can potentially decrease susceptibility to 
experiencing these common side effects. 
Complementary and alternative medicine (CAM) therapies are non-traditional medical 
practices performed with the intent to treat or prevent a condition. There are various forms of 
CAM therapies, which may include homeopathy, naturopathy, meditation and prayer, herbal and 
dietary supplements, chiropractic and massage therapy, and energy therapies (NCCIH 2000). 
Among adults with arthritis, the use of dietary supplements is one form of CAM that is becoming 
widely used. Glucosamine and chondroitin are two supplements of interest. Glucosamine and 
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chondroitin can be found separately or in combination pills. Both supplements are thought to 
have a role in protecting joints from degeneration (Gibson et al. 2014; Stuber et al. 2011). The 
classification of glucosamine and chondroitin as dietary supplements instead of pharmaceutical 
drugs mean that they are not approved by the U.S Food and Drug Administration (FDA) for 
medicinal use. However, the two supplements are typically safe to use (Barnes et al. 2008; 
Dahmer & Schiller 2008). Currently, glucosamine and chondroitin, alone or in combination, are 
marketed towards persons with arthritis. Glucosamine is also often used as a preventive measure 
to maintain health, and has been identified as a potential treatment for pain relief of degenerative 
disc disease (Hopman et al. 2006; Stuber et al. 2011). Glucosamine and chondroitin are of 
particular interest because they could potentially be an effective way to reduce pain and restore 
joint function in persons with arthritis while decreasing risk of adverse side effects.  
While glucosamine and chondroitin appears to show some promise in reducing pain and 
restoring joint function in persons with arthritis, findings from multiple studies have been 
inconclusive about their true effectiveness in these functions. While some studies are finding 
glucosamine and chondroitin to be moderately effective in decreasing pain and stopping the 
progression of osteoarthritis (Bruyere & Reginster 2007; McAlindon et al. 2000), others are 
finding the supplements to be no more effective than placebos (Clegg et al. 2006; Kwoh et al. 
2014). What is also less understood is the proportion of adults with arthritis who use 
glucosamine and/or chondroitin and derive any benefits from its use such as positive quality of 
life or improved health and decreased pain. This study will contribute to this gap. 
3 
 
 
RESEARCH QUESTIONS AND HYPOTHESES 
1. What are the socio-demographic characteristics of U.S. adults with any arthritis, unspecified 
arthritis and rheumatoid arthritis?  
2. What are the socio-demographic characteristics of U.S. adults with any arthritis, unspecified 
arthritis, and rheumatoid arthritis who use glucosamine and/or chondroitin?  
3. Does self-reported improved health or joint pain, aching, and stiffness among U.S. adults with 
any arthritis, unspecified arthritis, and rheumatoid arthritis differ based on glucosamine and/or 
chondroitin use?  
 H10: Adults with any arthritis who report using glucosamine and/or chondroitin will not 
differ from adults who do not use glucosamine and /or chondroitin on self-reported health 
improvement in the past 12 months. 
 H20: Adults with unspecified arthritis who report using glucosamine and /or chondroitin 
will not differ from adults who do not use glucosamine and /or chondroitin on self-
reported health improvement in the past 12 months. 
 H30: Adults with rheumatoid arthritis who report using glucosamine and /or chondroitin 
will not differ from adults who do not use glucosamine and /or chondroitin on self-
reported health improvement in the past 12 months. 
 H40: Adults with any arthritis who report current glucosamine and/or chondroitin use will 
not differ from adults who do not use glucosamine and /or chondroitin on self-reported 
symptoms of joint pain, aching, and stiffness in the past 30 days. 
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 H50: Adults with unspecified arthritis who report current glucosamine and /or chondroitin 
use will not differ from adults who do not use glucosamine and /or chondroitin on self-
reported symptoms of joint pain, aching, and stiffness in the past 30 days. 
 H60: Adults with rheumatoid arthritis who report current glucosamine and /or chondroitin 
use will not differ from adults who do not use glucosamine and /or chondroitin on self-
reported symptoms of joint pain, aching, and stiffness in the past 30 days. 
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CHAPTER II 
 REVIEW OF LITERATURE 
OVERVIEW OF ARTHRITIS 
Arthritis is the inflammation of one or more of joints, with osteoarthritis and rheumatoid 
arthritis as the most common forms of arthritis (CDC 2014). Arthritic symptoms include pain, 
aching, and swelling around the joints. Arthritis is the leading cause of disability and among the 
leading causes of work limitations in adults (Helmick et al. 2008). 
Though anyone can be affected, arthritis tends to be an illness of the aging population and 
is most common among adults aged 65 years or older (CDC 2014).  While the prevalence of 
juvenile arthritis is often difficult to estimate due to differences in nomenclature and a consistent 
case definition, NHIS data suggests a prevalence of 150 per 100,000 for all types of childhood 
arthritis (Helmick et al. 2008). In addition to age, sex and weight are risk factors for arthritis 
(CDC 2014).  
In 2003, an estimated $128 billion in medical-care costs and lost earnings were due to 
arthritis alone in the United States (CDC 2007). Analyzed data from the National Health 
Interview Survey (NHIS) for years 2010-2012 found that 52.5 million (22.7%) of adults ages 18 
years or older self-reported doctor-diagnosed arthritis. Of these people, 22.7 million reported 
being limited in physical activity due to having arthritis. In addition, the prevalence of arthritis in 
this population is greater among persons with other health complications when compared to the 
general population prevalence of 22.7%. For example, the prevalence of doctor-diagnosed 
arthritis among obese adults, persons with diabetes, and persons with heart disease was 31.2%, 
47.3%, and 49.0% respectively (Barbour et al. 2013). Equally alarming is the prevalence of 
persons with these conditions being limited in activity due to arthritis; the prevalence is 26.8%, 
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25.7%, and 15.2%, respectively. With arthritis driving cost and physically limiting the work 
force, it is increasingly becoming a public health concern. 
OSTEOARTHRITIS 
Osteoarthritis is the most common form of arthritis and is characterized by progressive 
degeneration of articular cartilage (Gibson et al. 2014). This disease is estimated to affect 
approximately 15% of the population. The primary location of osteoarthritis is commonly seen in 
the knee and hip, which is the leading cause of lower extremity disability amongst older adults 
(Johnson & Hunter 2014). While the etiology of osteoarthritis is not fully understood, disease 
progression can be divided into two phases at the cellular level: a biosynthetic phase and a 
degenerative phase (Gibson et al. 2014). Chondrocytes are the mature cells found in cartilage. 
These cells are partly responsible for maintaining the extracellular matrix (Mollenhauer 2008). 
The biosynthesis phase begins when the extracellular matrix is damaged and the chondrocytes 
fails to repair it. When this occurs, production of the extracellular matrix is inhibited causing 
chondrocytes to release proteolytic enzymes, accelerating cartilage loss. This begins the 
degenerative phase. By products of the extracellular matrix travel throughout the joint, creating 
build up and inflammation that contributes to further disease progression (Hunziker 2002; 
Mollenhauer 2008). 
Because osteoarthritis is the result of the complex interaction between mechanical, 
cellular, and biomechanical factors, there are several associated risk factors, which include: age, 
gender, genetics, obesity, diet, and occupational and physical activity. Johnson and Hunter 
identifies the increased risk of incident osteoarthritis through two categories: susceptible joints 
and predisposed individual (Johnson & Hunter 2014). Susceptible joint is determined by five 
modifiable risk factors: muscle strength, physical activity/occupation, joint injury, joint 
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alignment, and leg length inequality. Predisposed individuals, on the other hand, are determined 
through two additional categories: modifiable systemic risk factors and non-modifiable systemic 
risk factors. Modifiable systemic risk factors include: obesity, diet, and bone metabolism. Non-
modifiable systemic risk factors include: age, sex, genetics, and ethnicity. 
Osteoarthritis can be ascertained using three different diagnostic approaches: pathological 
screening, radiographical screening, or clinical screening (Johnson & Hunter 2014). Typically, 
diagnosis is made using a radiographical or clinical screening. Clinically diagnosed osteoarthritis 
is based on the examination revealing characteristic symptomology. Radiographical diagnosis of 
osteoarthritis is based on graded radiographs according to the Kellgen and Lawrence (KL) 
grading system. The KL grading system grades on a scale of 0 to 4. It assesses the severity of the 
disease on a plain radiograph based on the visibility of joint space narrowing, osteocytes, and 
bone deformity. Any grade greater than 2 results in a diagnosis of osteoarthritis (Johnson & 
Hunter 2014). According to Elders, an estimated 60% of the United States’ population develops 
radiographic evidence of osteoarthritis by the time they reach age 55 (Elders et al. 2000). 
Radiographic knee and hip osteoarthritis each had a prevalence of 28% in the Johnston 
County Osteoarthritis Project of African American and Caucasian men and women (Jordan et al. 
2007; Jordan et al. 2009). These two studies also found reported prevalence rates of 17% 
symptomatic knee osteoarthritis and 10% for symptomatic hip osteoarthritis. These prevalence 
rates are different because all persons with radiographic osteoarthritis do not experience 
concomitant symptoms (Johnson & Hunter 2014). 
 A Sweden population based study found a proportion of 26.6% of persons aged 45 years 
and older with any doctor-diagnosed osteoarthritis. The proportion of women, 30.5%, was higher 
than the proportion of men, 22.4%. About 27% of the prevalent cases had osteoarthritis in 
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multiple joints (Turkiewicz et al. 2014). Prevalence of radiographic knee osteoarthritis in the 
United States is 52.4% in African Americans, 36.2% in Whites, and 37.6% in Mexican 
Americans (Lawrence et al. 2008).The prevalence is significantly higher in African Americans 
when compared to Whites and Mexican Americans.  
RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a chronic inflammatory disease that results in damage to bone and 
cartilage. It is a term that includes several rheumatic diseases and conditions such as rheumatoid 
arthritis, lupus, osteoarthritis, fibromyalgia, and gout. Symptoms of this condition include 
fatigue, pain, and other extra-articular manifestations (Md Yusof & Emery 2013). Rheumatoid 
arthritis is a fairly common disease that occurs two to three times more frequently in women than 
in men (Gabriel 2001; Smolen & Steiner 2003). While it can occur at any age, prevalence peaks 
are most common in the 4th and 6th decade of life. The most commonly affected joints are those 
of the hands, feet, and knees (Smolen & Steiner 2003). While obesity is associated with 
increased risk of arthritis, being underweight due to weight loss is associated with accelerated 
mortality in rheumatoid arthritis (Baker et al. 2015).  
The cause of rheumatoid arthritis is unknown. It is thought to have a polygenic basis 
although the genes involved in pathogenesis have yet to be identified (Smolen & Steiner 2003). 
What is clear is that rheumatoid arthritis is initiated by CD4+ T cells. These cells amplify the 
immune response by stimulating other mononuclear cells, synovial fibroblasts, chondrocytes, 
and osteoclasts. Cytokines such as TNF-a, interleukin-1, and interleukin-6 are released resulting 
in synovial inflammation (Choy & Panayi 2001). Long term inflammation results in the joint 
damage that is associated with rheumatoid arthritis. Patients with arthritis have synovial 
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membranes that are characterized by hyperplasia, increased vascularity, and an infiltrate of 
inflammatory cells such as CD4+cells (Smolen & Steiner 2003).  
About half of the patients newly diagnosed with rheumatoid arthritis are 65 years of age 
and older (Waljee et al. 2015). A Quebec study found a prevalence of 9.9 per 1,000. This study 
found a male prevalence of 4.1 per thousand and female prevalence of 5.6 per 1,000. In addition, 
older women had a higher prevalence for any demographic group (Bernatsky et al 2014). A US 
study analyzing data from Olmsted County, Minnesota from 1955 to 2006 found that the overall 
annual age and sex adjusted rheumatoid arthritis incidence was about 40.9 per 100,000 
(Myasoedova et al. 2010). Age adjusted incidence in women was much higher than in men. 
Women had an age adjusted incidence of 53.1 per 100,000 while men had an age adjusted 
incidence of 27.7 per 100,000. When extrapolated to the US population, 1.5 million US adults 
were estimated to have arthritis in 2007 compared to 1.3 million reported in 1995 (Myasoedova 
et al. 2010). 
CURRENT TREATMENT 
Pharmacological therapy for osteoarthritis and rheumatoid arthritis mostly consists of 
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). This is particularly alarming 
because the overuse of these drugs could cause serious adverse gastrointestinal and 
cardiovascular events (Wu et al. 2013). In addition, analgesics and NSAIDs do not improve the 
underlying structural cartilage damage. Patients with symptomatic hip or knee osteoarthritis that 
use non-steroidal anti-inflammatory drugs are typically advised to use the lowest effective dose 
and avoid long-term use if possible (Wu et al. 2013). In severe cases, joint replacement surgeries 
may be deemed necessary.  
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Disease-modifying anti-rheumatic drugs (DMARDs) are becoming more readily 
available for rheumatoid arthritis (Smolen & Steiner 2003). Early therapy intervention can lead 
to better disease control and lessen joint damage.  Because treatment with disease-modifying 
anti-rheumatic drugs (DMARDs) is only justified when the risk-benefit or cost-effectiveness 
ratios are favorable, early detection is necessary for the use of these drugs (Visser et al. 2002). 
Patients diagnosed at a later stage or who have had rheumatoid arthritis over a long period of 
time, may have less pharmacological options and therefore may resort to complementary and 
alternative medicine (CAM) therapies. 
ALTERNATIVE THERAPIES FOR ARTHRITIS 
Complementary and Alternative Medicine (CAM) therapies are treatment/prevention 
strategies not considered to be a biomedical intervention. CAM therapies are becoming 
increasingly difficult to define, as it includes a broad range of systems and strategies.  
Throughout the literature, there is a lack of consistency of what should be considered CAM 
therapies. This is partly due to scientific evidence that may or may not support these therapies 
but, also due to political ramifications. Licensure is a sure form of recognition for any therapy 
however, not all CAM therapies are licensed or many have few or no formal regulation. 
Chiropractic, acupuncture, and massage therapy are licensed in most states while naturopathy 
and homeopathy are licensed in fewer (Johnson & Hunter 2014).  
While there are several CAM therapy classification systems, the most widely used 
classification structure was developed by the National Center for Complementary and Integrative 
Health (NCCIH), formerly known as the National Center for Complementary and Alternative 
Medicine (NCCAM) (Kaptchuk & Eisenberg 2001; NCCIH 2000). According to this 
classification system, there are five categories of CAM modalities: alternative medical systems, 
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mind-body interventions, biologically based treatments, manipulative and body-based methods, 
and energy therapies (NCCIH 2000). Alternative medical systems refer to a paradigm or system 
of theory that is not of conventional medicine. Homeopathy, Acupuncture, Ayurveda, and 
naturopathy are example of alternative medical systems. Mind-body interventions are therapies 
that are used to bring awareness to how stress, thoughts, and feelings can impact our physical 
health. Mind-body interventions are typically those that help to reduce the “fight or flight” 
response, which occurs during times of stress and which is used to calm the mind and assist in 
emotional regulation. Meditation and prayer are just two examples of mind-body therapies, but 
there are many others.  Chiropractic and massage therapies are classified as manipulative and 
body-based, which work towards aligning and reducing muscle tension, which often result from 
physical or emotional stress and trauma. Energy therapies consist of the manipulation and 
application of energy fields to the body. In the same way that electromagnetic fields exist outside 
of the body, these therapies rely on the assumption that there too exist energy fields within the 
body. Reiki and Qi Gong are examples of this classification type. Finally, biological based 
therapies use herbal products, dietary supplements, hormones, and other natural products 
(NCCIH 2000). 
Several CAM therapies have been identified as being effective in symptom relief of 
arthritic conditions such as acupuncture, energy, chiropractic/osteopathic, and mind-body 
therapies, and dietary supplements- namely glucosamine and chondroitin. For example, a 2013 
meta-analysis of physical treatments that included 114 trials, found acupuncture to be more 
strongly associated with pain reduction than standard care among persons with osteoarthritis of 
the knee (Corbett et al. 2013). A 2009 study of 40 patients with a mean age of 65 years found Tai 
Chi to be effective in reducing pain and improving physical function and self-efficacy. It also 
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showed benefits for improving depression and health-related quality of life for knee osteoarthritis 
(Wang et al. 2009). A systematic review on use of yoga for persons with arthritis found yoga to 
be effective in improving self-efficacy and mental health, and in symptom reduction such as 
tender/swollen joints, pain, and disability (Haaz & Bartlett 2011). In a clinical pilot trial, persons 
with hip osteoarthritis waiting for arthroplasty, chiropractic therapy was proven to be effective in 
improving self-rated hip pain, function in daily living, and hip related quality of life (Thorman et 
al. 2010). In addition, a randomized clinical trial found that relaxation response training 
significantly improves pain associated with rheumatoid arthritis (Barsky et al. 2010). This thesis 
recognizes that there are other forms of CAM therapies that can influence reports of improved 
health and joint pain, aching, and stiffness however, will focus on these outcome relationships 
with glucosamine and/or chondroitin use. These other CAM therapies will be considered 
potential covariates. 
GLUCOSAMINE 
Glucosamine is a naturally occurring amino-monosaccharide that is thought to be active 
in protecting joints from degeneration (Gibson et al. 2014). It is an integral part of the normal 
growth and repair of connective tissues (Henrotin et al. 2013). Glucosamine is a preferred 
substrate for the production of aggrecans and other proteoglycans in cartilage (Wu et al. 2013). 
As one of the major constituents of the extracellular matrix (ECM), its potential 
chondroprotective properties are key. Glucosamine supplements can be found on the shelves of 
pharmacies and many grocery stores and are commonly sold in two forms: glucosamine sulfate 
and glucosamine hydrochloride.  Of the two, glucosamine sulfate has been identified as the more 
promising supplement in alleviating pain and symptoms associated with arthritis due to its 
structure and function (Henrotin et al. 2013).  
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 Glucosamine is currently classified as a dietary supplement and not a drug, therefore is 
not approved by the U.S Food and Drug Administration (FDA) for medicinal use (Barnes et al. 
2008). However, glucosamine is among the most commonly used CAM treatments among 
persons with arthritis. For example, when current CAM use was observed in a study of 612 
patients with arthritis, glucosamine use (about 34.1%) was reported the most (Herman et al. 
2004). In addition to use for arthritic symptoms, glucosamine is also used as a preventive 
measure to maintain health, and has been identified as a potential treatment for pain relief of 
degenerative disc disease (Hopman et al. 2006; Stuber et al. 2011). Reported adverse effects of 
glucosamine are generally uncommon and minor (Dahmer & Schiller 2008). However, 
intravenous administration of glucosamine was shown to cause insulin resistance and endothelial 
dysfunction in animal models. A 2006 study set out to determine if oral glucosamine is likely to 
cause or worsen these conditions in lean or obese subjects (Muniyappa et al. 2006). Findings 
from this study suggest that standard doses of oral glucosamine for six weeks does not cause or 
worsen insulin resistance or endothelial dysfunction in lean or obese subjects. 
CHONDROITIN 
Chondroitin is often found in combination supplement pills with glucosamine. Because 
chondroitin constitutes the majority of the glycosaminoglycans in articular cartilage, it is 
speculated to be active in maintaining the viscosity in joints, stimulating cartilage repair, and 
inhibiting enzymes responsible for cartilage degeneration (Stuber et al. 2011). For this reason, it 
is mostly used among persons with arthritis to decrease pain and other associated symptoms 
through its potential structural modifying effects. While chondroitin is considered a generally 
safe supplement, similar to glucosamine, chondroitin is classified as a dietary supplement and 
therefore, is not approved by FDA for medicinal purposes (Barnes et al. 2008).  
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SOCIODEMOGRAPHICS OF GLUCOSAMINE/CHONDROITIN USE 
A 2008 study analyzing 2007 National Health Interview Survey (NHIS) data found that 
38% of adults 18 years and older in the Northeast region were CAM users while 41.4% were 
users in the Midwest, 32.5% in the South, and 44% in the West. This same study shows that 
persons age 50-59 years of age had the highest prevalence of CAM use (Barnes et al. 2008). In a 
study observing CAM use among overweight and obese persons with radiographic knee 
osteoarthritis, BMI was inversely associated with CAM use. Persons classified as obese (BMI 
≥30 kg/m2) were less likely to use CAM therapies, alone or in combination with conventional 
medications when compared to persons underweight or normal weight (BMI <25 kg/m
2
) (Lapane 
et al. 2013).  While there are studies on the distribution of general use of complementary and 
alternative therapies (CAM), less is known about glucosamine and/or chondroitin use. 
Understanding the socio-demographic characteristics of glucosamine and/or chondroitin use is 
important for this thesis. 
An Australian study of persons 45 years of age and older found that higher income is 
associated with glucosamine use (Sibbritt et al. 2012). A Canadian study, similarly, found that 
glucosamine use occurred more in the western regions when compared to all other regions 
(Hopman et al. 2006). In addition, it is estimated that almost 400,000 elderly diabetic persons in 
the U.S use glucosamine (Simon et al. 2011).  
A 2006 study using the US Food and Administration 2002 Health and Diet Survey found 
that glucosamine sulfate or glucosamine and chondroitin constituted 10.9% of the use of specific 
herbs, botanicals, and other nonvitamin/nonmineral dietary supplements during the past 12 
months (Timbo et al. 2006). Prevalence of persons using chondroitin 45 to 64 years of age was 
2.3% while prevalence of its use for persons 65 years of age and older was 3.9% in 2002. The 
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prevalence of chondroitin use in 2002 has increased since 1998/1999 (Kelly et al. 2005). 
However, there has been 12 years since this study. This thesis will determine if changes in 
chondroitin use has changed since 2002. 
CLINICAL STUDIES 
A systematic review conducted by Bruyere and Reginster, which included eight primary 
trials over a 12 month period, found glucosamine sulfate and chondroitin to be effective in 
showing improvements in joint space loss, pain, and function (Bruyere & Reginster 2007). The 
same review, analyzing two additional studies, found glucosamine sulfate to reduce the need for 
knee arthroplasty from 14.5% to 6.3% at eight years’ follow-up. This study concluded that there 
is evidence that glucosamine sulfate and chondroitin sulfate may interfere with progression of 
osteoarthritis with respect to the structure modifying effect (Bruyere & Reginster 2007). 
Similarly, a systematic quality assessment and meta-analysis conducted by McAlindon 
also found glucosamine and chondroitin to demonstrate moderate to large effects in decreasing 
symptoms of osteoarthritis (McAlindon et al. 2000). This study included 15 double-blind, 
randomized, placebo-controlled trials lasting 4 or more weeks from 1996 to June 1999. Only 
those analyzing glucosamine or chondroitin for knee or hip osteoarthritis with reported 
extractable data on the effect of treatment on symptoms were included. Findings may have been 
exaggerated due to quality issues and likely publication bias. The authors admit that several of 
the analyzed studies were conducted by manufacturers. Although the extent to which 
glucosamine or chondroitin was effective is unknown, this study has enough evidence to 
suggests that glucosamine and chondroitin does exhibit some effectiveness in decreasing 
symptoms of osteoarthritis. 
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On the other hand, a study conducted by Kwoh concluded that there are no structural 
benefits of glucosamine supplementation particularly in individuals with chronic knee pain 
(Kwoh et al. 2014). This randomized, placebo-controlled clinical trial, included 201 participants 
with mild-to-moderate pain in one or both knees, as defined by a Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC). Participants received 1,500 mg glucosamine 
hydrochloride in beverage form or a placebo beverage over the duration of 24 weeks. The 
adjusted odds ratio for the likelihood of cartilage damage decreasing over 24 weeks in the 
glucosamine treatment group compared to the control group was 0.938 (Kwoh et al. 2014). This 
short-term study concluded that there is no evidence to support the idea that glucosamine 
supplementation in individuals with chronic knee pain possesses some structural benefits. 
The conclusion of the study conducted by Clegg coincides with those from the Kwoh et 
al. (2014) study. A total of 1,583 patients with symptomatic knee osteoarthritis participated in 
this study. Patients were randomly assigned to one of five groups where they could receive 1,500 
mg of glucosamine daily or 1,200 mg of chondroitin sulfate daily or both glucosamine and 
chondroitin sulfate or 200 mg of celecoxib daily or placebo for 24 weeks (Clegg et al. 2006). 
This study found that the use of glucosamine and chondroitin sulfate, alone or in combination, 
were not significantly better than placebo in reducing knee pain by 20 percent. 
While there are several clinical trials and systematic reviews on glucosamine and/or 
chondroitin and arthritis, observational studies are scarce. An observational study by Jawahar et 
al. (2012) found that the use of complementary and alternative medicine (CAM) either alone or 
in combination with prescription medicine was common among individuals with knee 
osteoarthritis. Findings from this study also suggest that glucosamine and/or chondroitin use 
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does not differ by gender among complementary and alternative medicine users (Jawahar et al. 
2012). 
Additional studies and analyses are needed to better understand socio-demographic 
characteristics of adults with arthritis who use glucosamine and/or chondroitin. Determining 
whether the use of these supplements result in self-reported improved health and decreased joint 
pain, aching, and stiffness when compared to those who do not use these supplements are 
important. This study utilizes 2012 National Health Interview Survey (NHIS) data to provide 
cross-sectional analyses. The association of glucosamine and/or chondroitin use one or more 
times within the past 12 months and reports of improved health when compared to 12 months 
ago is one relationship that will be analyzed. The association between glucosamine and/or 
chondroitin use within the past 30 days and self-reported symptoms of joint pain, aching, and 
stiffness in the past 30 days will also be analyzed. While previous clinical studies have included 
ways to account for the effect that dose may have in such associations, this study will analyze 
glucosamine and/or chondroitin use as a four level variable: glucosamine only, chondroitin only, 
neither glucosamine nor chondroitin, and both glucosamine and chondroitin.  
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CHAPTER III 
METHODOLOGY 
DATA SOURCE 
 The 2012 National Health Interview Survey (NHIS), a cross-sectional household 
interview survey, was used for this study. This data source is provided through the National 
Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC). 
NHIS has been continuously collected since July of 1957 to provide national estimates for 
healthcare utilization and access, health indicators, and health related behaviors for the U.S. 
civilian noninstitutionalized residents. Participants are recruited through a cost-effective complex 
sampling frame which includes multistage stratification, clustering, and differential sampling 
rates. Weights are adjusted based on the 2010 U.S census data. Black, Hispanic, and Asian 
persons are oversampled and Black, Hispanic, or Asian persons aged 65 years have increased 
chances of being selected. Participants are drawn from each state and the District of Columbia to 
be nationally representative for the U.S civilian noninstitutionalized population. 
The NHIS consists of four main components that are included each year: The Household 
Composition Section, the Family Core questionnaire, the Sample Child Core, and the Sample 
Adult Core. The Household Composition Section asks basic demographic and relationship 
information on persons within the household. Because several families can live within one 
household, The Family Core questionnaire is administered to each family within a household. 
This questionnaire collects information on all persons in the family on topics related to health 
status, health insurance coverage, and access and utilization of health care services. The Sample 
Child Core is administered to one child 17 years of age or younger if present. The Sample Adult 
Core is administered to one adult 18 years of age or older. An emancipated minor is not eligible 
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to participate in the Sample Child or the Sample Adult survey. Supplemental questionnaires are 
included at different time intervals. The Adult Alternative Medicine and Child Alternative 
Medicine questionnaires have been included every five years since 2002. The 2012 NHIS 
consisted of eight data files. Because the adult population was the population of interest for this 
study, only four of the eight data files were merged: Sample Adult file, Adult Alternative 
Medicine Household file, and Family file. 
APPROVAL 
This thesis utilizes secondary public use data and did not require Institutional Review 
Board (IRB) approval. The NHIS is a preapproved data source with exempt status determined by 
the Georgia State University IRB (Institutional Review Board Policies). 
INCLUSION AND EXCLUSION CRITERIA 
While the adult sample consisted of 34,525 persons 18 years of age and older, persons 
with missing responses to any of the questions used for this analysis were excluded from the 
analysis of the study, resulting in a population size of 32,385 as shown in Figure 1. Furthermore, 
because the subpopulation of interest are adults with arthritis, the sample was restricted to 
persons that answered “yes” to: “Have you ever been told by a doctor or other health 
professional that you have some form of arthritis, rheumatoid arthritis, gout, lupus, or 
fibromyalgia?” Responses of “yes” to this question will be referred to as “any arthritis” 
throughout this paper. Further analysis was conducted on subpopulations of persons that 
responded “arthritis” and/or “rheumatoid arthritis” to the follow up question: “You just 
mentioned that you were told by a doctor or other health professional that you had some form of 
arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia. Which of these were you told you 
had?” A person is classified as having “unspecified arthritis” if they responded “arthritis” to the 
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follow up question. Likewise, a person is classified as having “rheumatoid arthritis” if they 
responded “rheumatoid arthritis” to this question. Figure 1 illustrates the three subgroups: any 
arthritis, unspecified arthritis, and rheumatoid arthritis. 
 
INDEPENDENT VARIABLES 
All variables of interest were assessed through self-reported data. Use of glucosamine 
and/or chondroitin was assessed over two different time intervals. The first assessment was use 
within the past 12-months. The second assessment was use within the past 30 days. These 
variables are used as four level variables: “no supplemental use”, “glucosamine only”, 
“chondroitin only”, and “both”. A person is determined to have “no supplemental use” if they 
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respond neither “glucosamine” nor “chondroitin” to:  “Please tell me which of these supplements 
you have taken during the past 12 months?” or “Which of these supplements have you taken 
during the past 30 days?” Using these same questions, a person was determined to use 
“glucosamine only” if they respond “glucosamine” but did not respond “chondroitin” to these 
questions. A person was determined to use “chondroitin only” if they respond “chondroitin” but 
not “glucosamine” to these questions. Finally, a person was determined to be a user of “both” if 
the respond both “glucosamine” and “chondroitin” to these questions. 
Demographics were placed into variable categories based on survey responses from the 
Adult Sample questionnaire. Sex is used as a dichotomized variable, “men” and “women”. Age 
was used as a categorical variable where categories were “18-39 years old”, “40-55 years old”, 
“56-70 years old”, “70-84 years old”, and “≥85 years old.” Region, education, and race were also 
categorical variables. The categories for region are “Northeast”, “Midwest”, “South”, and 
“West”. Education was documented as the highest level of education achieved by a family 
member. These categories are “Did Not Complete High School”, “GED”, “High School 
Diploma”, “Some College, No Degree”, “Associate’s Degree”, “Bachelor's Degree”, and 
“Master's, Professional, or   Doctoral Degree”. Race categories are “White”, “Black/African 
American”, “Hispanic/Latino”, “American Indian or Alaskan Native”, and “Asian”. Poverty 
level is a calculated variable in the public release data. Because poverty level was missing about 
8.2% as shown in Table 1, poverty level was used as a three level variable, “Above Poverty 
Line”, “At or Below Poverty Line”, and “Unknown” to eliminate missing. 
To achieve better estimates, other health conditions and BMI were also analyzed. A 
dichotomized variable for other health conditions was created in which a person determined to 
have “other health conditions” responded “yes” to being told by a doctor or other health 
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professional that they had either diabetes (except when pregnant if female) or a heart condition. 
Because BMI is a risk factor for arthritis, it is also included (CDC 2014). Because BMI is 
associated with certain forms of arthritis, BMI was used as a three level variable where 
categories are “≤ 24.9”, “>24.9 and <30.0”, and “≥ 30.0” to identify persons that are underweight 
and normal weight, overweight, and obese.  
To control for confounding with other therapies used by respondents, the following were 
categorized as dichotomous variables if respondents reported the use of therapies, either 
themselves or with a professional, within the past 12 months: chiropractic or osteopathic 
manipulation, energy therapies, mind-body therapies, and acupuncture. In previous studies, all of 
these CAM therapies were described as potentially being effective in improving health and/or 
decreasing pain (Corbett et al. 2013; Wang et al. 2009; Haaz & Bartlett 2011; Thorman et al. 
2010; Barsky et al. 2010). Energy therapies include the use of Yoga, Tai Chi, and Qi Gong. 
Mind-body therapies include the use of Mantra Meditation, Mindful Meditation, Spiritual 
Meditation, Guided Imagery, and Progressive Relaxation. While Yoga and Tai Chi are often 
classified as Mind-body therapies as well, they will be considered energy therapies for this thesis 
to be consistent with the 2012 NHIS classifications and to prevent Qi Gong from representing 
this category alone. 
DEPENDENT VARIABLES 
 This study has two dependent variables. The first dependent variable assessed in this 
thesis is improved health in the past 12-months. A person is determined to have “improved 
health” if they respond “better” to: “Compared with 12 months ago, would you say your health is 
better, worse, or about the same?” Likewise, a person is determined to have “unimproved health” 
if they responded “worse” or “about the same” to this question. The other dependent variable 
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assessed in this thesis is joint pain, aching, and stiffness in the past 30 days. A person is 
determined to have “pain” if they respond “yes” to: “During the past 30 days, have you had any 
symptoms of pain, aching, or stiffness in or around a joint?” If a person answered “no” to this 
question, they are then classified as having “no pain”. 
 
Table 1: Missing Variables in the 2012 National Health Interview Survey (NHIS) 
2012 NHIS Adult Sample 
N= 34525 
Characteristics Not Missing Missing % Missing 
Any Arthritis 34485 40 0.1 
Unspecified Arthritis 34473 52 0.2 
Rheumatoid Arthritis 34473 52 0.2 
12 Month Glucosamine Use 34495 30 0.1 
30 Day Glucosamine Use 34525 0 0.0 
12 Month Chondroitin Use 34495 30 0.2 
30 Day Chondroitin Use 34525 0 0.0 
Sex 34525 0 0.0 
Age 34525 0 0.0 
Race/Ethnicity 33919 606 1.5 
BMI 33170 1355 4.1 
Education 34457 68 0.1 
Poverty Level 31661 2864 8.2 
Poverty Level Recode* 34525 0 0.0 
Region 34525 0 0.0 
Other Health Conditions 34488 37 0.1 
Energy Therapies 34522 3 0.0 
Acupuncture 34525 0 0.0 
Mind-Body Therapies 34524 1 0.0 
Chiropractic/ Osteopathic Therapy 34521 4 0.2 
Total** 32385 2140 6.0 
*Poverty was recoded from a bivariate to a three level variable to eliminate missing. 
**The calculated total uses the recoded variable of poverty level. It is important to note that this total is  
 not a simple tally of all missing variables but a count of all persons with at least one missing variable. 
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DATA ANALYSIS 
 All analyses for this study were conducted using Statistical Analysis System 9.4 (SAS 
9.4). The analysis accounted for the survey design and nonresponse using SAS survey 
procedures. All estimates were weighted to the U.S. population to generate nationally 
representative estimates based on 2010 U.S. census data. 
Descriptive statistics were used to summarize characteristics that are potential risk or 
protective factors for arthritis. Frequency distributions are used to identify the proportion of the 
2012 National Health Interview Survey (NHIS) population that has any arthritis, unspecified 
arthritis, and rheumatoid arthritis. It is also used to identify glucosamine and/or chondroitin use 
within the past 12 months and within the past 30 days of the administration of the 2012 NHIS 
among these subgroups. 
Logistic regressions were used to conduct bivariate analyses of selected characteristics 
and reports of improved health over a 12 month period among persons with each any arthritis, 
unspecified arthritis, and rheumatoid arthritis. Logistic regressions were also used to conduct 
bivariate analyses of selected characteristics and reports of joint pain, aching, and stiffness in the 
past 30 days among persons with each any arthritis, unspecified arthritis, and rheumatoid 
arthritis. Because chondroitin only and both glucosamine and chondroitin use within the past 30 
days among persons with rheumatoid arthritis was unable to be observed due to small sample 
size, past 30 day glucosamine use was modeled as a bivariate variable: “no glucosamine use” and 
“glucosamine use”. All of these analyses were then used to identify possible confounding.  
Logistic multivariate regression models were built using all selected CAM therapies 
(energy therapies, acupuncture, mind-body therapies, chiropractic/osteopathic therapy) and 
demographics that yielded statistically significant odds ratios in the bivariate analyses. The level 
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of significance was alpha= 0.05. Different models were fit to quantify the associations of 
glucosamine and/or chondroitin use within the past 12 months and self-reported improved health 
when compared to 12 months ago among persons with each any arthritis, unspecified arthritis, 
and rheumatoid arthritis. The same was done to quantify the associations of glucosamine and/or 
chondroitin use within the past 30 days and reports of joint pain, aching, or stiffness in or around 
a joint over the past 30 days among persons with each any arthritis, unspecified arthritis. Due to 
the small sample size of chondroitin only and both glucosamine and chondroitin use within the 
past 30 days among persons with rheumatoid arthritis, past 30 day glucosamine use was 
dichotomized as: “no glucosamine use” and “glucosamine use”. 
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CHAPTER IV 
RESULTS 
DESCRIPTIVE STATISTICS 
 Approximately 21.8% of the U.S population had any arthritis in 2012 (Table 2); 17% had 
unspecified arthritis and 2.5% reported having rheumatoid arthritis. Women were more likely 
than men to report some form of arthritis. Approximately 25% of women reported having any 
arthritis, 19.7% reported having unspecified arthritis, and 3.2% reported having rheumatoid 
arthritis when compared to 18.4% of any arthritis, 14.2% unspecified arthritis and 1.7% 
rheumatoid arthritis among men. As can be seen in Table 2, prevalence of any arthritis, 
unspecified arthritis, and rheumatoid arthritis increases with age and BMI. In addition, persons 
with diabetes and/or heart conditions (other health conditions) had prevalence rates of some form 
of arthritis more than twice of that of persons who did not have other health conditions. Persons 
with other health conditions had a 44.2% prevalence of any arthritis, 34.8% of unspecified 
arthritis, and 5.4% of and rheumatoid arthritis. Persons that did not have other health conditions 
had a prevalence rate of 17.7% of any arthritis, 13.7% of unspecified arthritis, and 1.9% of 
rheumatoid arthritis. 
Table 2: Prevalence and Demographic Characteristics of Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and 
Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS) 
Adult Population 
N= 32385 
 
Characteristics 
 
No Arthritis 
n (% ) 
 
Any Arthritis 
n (%) 
No Unspecified 
Arthritis 
n (%) 
Unspecified 
Arthritis 
n (%) 
No Rheumatoid 
Arthritis 
n (%) 
Rheumatoid 
Arthritis 
n (%) 
Total 24731 (78.2) 7654 (21.8) 26369 (83.0) 6016 (17.0) 31487 (97.5) 898 (2.5) 
Sex 
     Men 
     Women 
 
11735 (81.6) 
12996 (75.0) 
 
2889 (18.4) 
4765 (25.0) 
 
12377 (85.8) 
13992 (80.3) 
 
2247 (14.2) 
3769 (19.7) 
 
14340 (98.3) 
17147 (96.8) 
 
284 (1.7) 
614 (3.2) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     >85 years old 
 
11019 (94.5) 
7003 (80.0) 
4472 (60.0) 
1819 (52.5) 
418 (47.4) 
 
662 (5.5) 
1826 (20.0) 
3030 (40.0) 
1669 (47.5) 
467 (52.6) 
 
11242 (96.3) 
7492 (85.3) 
5068 (67.8) 
2082 (60.3) 
485 (55.2) 
 
439 (3.7) 
1337 (14.7) 
2434 (32.2) 
1406 (39.7) 
400 (44.8) 
 
11594 (99.2) 
8582 (97.3) 
7157 (95.9) 
3320 (95.4) 
834 (94.5) 
 
87 (0.8) 
247 (2.7) 
345 (4.1) 
168 (4.6) 
51 (5.5) 
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Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
14261 (75.0) 
3614 (78.9) 
4808 (88.1) 
1799 (89.9) 
149 (76.0) 
 
5346 (25.0) 
1248 (21.1) 
777 (11.9) 
234 (10.1) 
49 (24.0) 
 
15444 (80.2) 
3917 (84.1) 
4990 (91.1) 
1853 (92.3) 
165 (84.7) 
 
4263 (19.8) 
945 (15.9) 
595 (8.9) 
180 (7.7) 
33 (15.3) 
 
19175 (97.5) 
4657 (96.4) 
5451 (97.8) 
2017 (99.1) 
187 (94.5) 
 
532 (2.5) 
205 (3.6) 
134 (2.2) 
16 (0.9) 
11 (5.5) 
BMI  
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
9781 (84.8) 
8588 (78.1) 
6362 (69.8) 
 
2051 (15.2) 
2629 (21.9) 
2974 (30.2) 
 
10205 (88.1) 
9137 (82.8) 
7027 (76.6) 
 
1627 (11.9) 
2080 (17.2) 
2309 (23.4) 
 
11586 (98.2) 
10940 (97.8) 
8961 (96.3) 
 
246 (1.8) 
277 (2.2) 
375 (3.7) 
Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or     
    Doctoral Degree 
 
2488 (75.2) 
549 (72.4) 
4630 (74.9) 
4941 (77.3) 
3138 (75.8) 
5411 (83.0) 
3574 (80.2) 
 
986 (24.8) 
221 (27.6) 
1698 (25.1) 
1554 (22.7) 
998 (24.2) 
1242 (17.0) 
955 (19.8) 
 
2652 (79.1) 
605 (79.8) 
5003 (80.3) 
5273 (82.3) 
3378 (82.0) 
5673 (86.4) 
3785 (84.9) 
 
822 (20.9) 
165 (20.2) 
1325 (19.7) 
1222 (17.7) 
758 (18.0) 
980 (13.6) 
744 (15.1) 
 
3348 (96.6) 
733 (95.5) 
6114 (96.9) 
6310 (97.4) 
3999 (96.7) 
6540 (98.6) 
4443 (98.2) 
 
126 (3.4) 
37 (4.5) 
214 (3.1) 
185 (2.6) 
137 (3.3) 
113 (1.4) 
86 (1.8) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
18603 (78.2) 
4305 (79.7) 
1823 (76.2) 
 
5753 (21.8) 
1254 (20.3) 
647 (23.8) 
 
19833 (82.9) 
4594 (84.6) 
1942 (80.6) 
 
4523 (17.1) 
965 (15.4) 
528 (19.4) 
 
23730 (97.6) 
5353 (96.9) 
2404 (97.5) 
 
626 (2.4) 
206 (3.1) 
66 (2.5) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
4131 (79.2) 
5057 (76.0) 
8907 (77.6) 
6636 (80.6) 
 
1281 (20.8) 
1712 (24.1) 
2924 (22.4) 
1737 (19.4) 
 
4394 (83.6) 
5385 (80.7) 
9566 (82.7) 
7024 (85.3) 
 
1018 (16.4) 
1384 (19.3) 
2265 (17.3) 
1349 (14.7) 
 
5255 (97.5) 
6595 (97.6) 
11467 (97.4) 
8170 (97.7) 
 
157 (2.5) 
174 (2.4) 
364 (2.6) 
203 (2.3) 
No Other Health Conditions 
Other Health Conditions 
21703 (82.3) 
3028 (55.8) 
5092 (17.7) 
2562 (44.2) 
22789 (86.3) 
3580 (65.2) 
4006 (13.7) 
2010 (34.8) 
26233 (98.1) 
5254 (94.6) 
562 (1.9) 
336 (5.4) 
No Energy Therapies  
Energy Therapies 
22265 (77.8) 
2466 (81.9) 
7073 (22.2) 
581 (18.1) 
23778 (82.7) 
2591 (85.6) 
5560 (17.3) 
456 (14.4) 
28498 (97.4) 
2989 (98.4) 
840 (2.6) 
58 (1.6) 
No Acupuncture 
Acupuncture 
24349 (78.4) 
382 (66.7) 
7456 (21.6) 
198 (33.3) 
25945 (83.1) 
424 (74.3) 
5860 (16.9) 
156 (25.7) 
30931 (97.5) 
556 (96.0) 
874 (2.5) 
24 (4.0) 
No Mind-Body Therapies 
Mind-Body Therapies 
23729 (78.5) 
1002 (71.1) 
7234 (21.5) 
420 (28.9) 
25261 (83.2) 
1108 (78.9) 
5702 (16.8) 
314 (21.1) 
30111 (97.6) 
1376 (96.9) 
852 (2.4) 
46 (3.1) 
No Chiropractic/ Osteopathic Therapy 
Chiropractic/ Osteopathic Therapy 
22755 (78.9) 
1976 (71.1) 
6780 (21.1) 
874 (28.9) 
24223 (83.6) 
2146 (76.7) 
5312 (16.4) 
704 (23.3) 
28715 (97.5) 
2772 (97.5) 
820 (2.5) 
78 (2.5) 
12 Month Supplement Use: 
    Neither 
    Glucosamine Only 
    Chondroitin Only 
    Both 
 
24127 (79.1) 
347 (56.8) 
44 (57.8) 
213 (47.8) 
 
7142 (20.9) 
267 (43.2) 
26 (42.2) 
219 (52.2) 
 
25679 (83.8) 
407 (66.2) 
46 (61.2) 
237 (53.8) 
 
5590 (16.2) 
207 (33.8) 
24 (38.8) 
195 (46.2) 
 
30424 (97.6) 
582 (96.9) 
67 (96.4) 
414 (96.3) 
 
845 (2.4) 
32 (3.1) 
3 (3.6) 
18 (3.7) 
30 Day Supplement Use: 
    Neither 
    Glucosamine Only 
    Chondroitin Only 
    Both 
 
24229 (78.9) 
353 (48.8) 
121 (71.8) 
28 (57.9) 
 
7244 (21.1) 
339 (51.2) 
45 (28.2) 
26 (42.1) 
 
25798 (83.6) 
405 (56.1) 
131 (78.7) 
35 (68.6) 
 
5675 (16.4) 
287 (43.9) 
35 (21.3) 
19 (31.4) 
 
30617 (97.6) 
658 (96.7) 
163 (96.3) 
49 (94.0) 
 
856 (2.4) 
34 (3.3) 
3 (3.7) 
5 (6.0) 
*This table presents unweighted frequencies and weighted row percentages. 
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Table 3 presents past 12 month glucosamine and/or chondroitin use among persons with 
any arthritis. Approximately 3.7% of persons with any arthritis use glucosamine, 0.4% use 
chondroitin, and 3.4% use both glucosamine and chondroitin. While glucosamine and both 
glucosamine and chondroitin users were more likely to be women (58.9% and 59.7% 
respectively), chondroitin users were more likely to be men (60.8%). Glucosamine, chondroitin, 
and both glucosamine and chondroitin users were more likely to be between the ages of 56 to 70 
(46.5%, 41.6%, and 57.3% respectively). Persons above the poverty line were more likely to be 
supplement users than persons below the poverty line or persons whom income level is 
unknown. Persons above the poverty line made up 91.3% of glucosamine use, 86.4% of 
chondroitin use, and 94.2% of both glucosamine and chondroitin use. While persons in the West 
made up the majority of glucosamine users (40.1%), persons in the Midwest made up the 
majority of chondroitin users (50.4). Persons in the Northeast had the lowest prevalence of any 
supplement use. In addition, more than a quarter of glucosamine users (27.7%) had other health 
conditions (diabetes and/or heart conditions).  
Table 3: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult 
Ages 18+ with Any Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Any Arthritis 
n= 7654 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 7142 (92.5) 267 (3.7) 26 (0.4) 219 (3.4) 
Sex 
     Men 
     Women 
 
2689 (41.5) 
4453 (58.5) 
 
99 (41.0) 
168 (58.9) 
 
12 (60.8) 
14 (39.2) 
 
89 (40.3) 
130 (59.7) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     >85 years old 
 
628 (10.0) 
1702 (26.8) 
2776 (38.5) 
1582 (19.7) 
454 (5.0) 
 
22 (9.1) 
72 (26.7) 
119 (46.5) 
48 (16.0) 
6 (1.8) 
 
0 (0.0) 
7 (37.8) 
11 (41.6) 
7 (17.2) 
1 (3.4) 
 
12 (6.8) 
45 (22.3) 
124 (57.3) 
32 (11.9) 
6 (1.7) 
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Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
4926 (76.7) 
1203 (11.6) 
748 (8.6) 
220 (2.5) 
45 (0.5) 
 
206 (83.4) 
29 (8.8) 
18 (5.0) 
11 (2.5) 
3 (0.3) 
 
23 (93.0) 
1 (3.3) 
2 (3.7) 
0 (0.0) 
0 (0.0) 
 
191 (91.0) 
15 (4.2) 
9 (3.1) 
3 (1.3) 
1 (0.5) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1925 (25.7) 
2442 (35.1) 
2775 (39.2) 
 
74 (28.1) 
95 (35.8) 
98 (36.0) 
 
6 (18.7) 
9 (38.7) 
11 (42.6) 
 
46 (20.0) 
83 (34.3) 
90 (45.7) 
Education 
    Did Not Complete High School 
    GED 
    High School  Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
973 (8.9) 
218 (2.6) 
1625 (21.3) 
1450 (20.8) 
912 (15.0) 
1127 (17.6) 
837 (13.8) 
 
8 (1.4) 
2 (0.1) 
47 (16.4) 
61 (20.8) 
39 (16.1) 
55 (21.1) 
55 (24.0) 
 
1 (1.9) 
0 (0.0) 
3 (8.9) 
5 (17.2) 
6 (29.4) 
4 (18.9) 
7 (23.7) 
 
4 (1.7) 
1 (0.6) 
23 (10.9) 
38 (14.7) 
41 (22.2) 
56 (26.4) 
56 (23.5) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
5291 (78.7) 
1227 (12.6) 
624 (8.6) 
 
239 (91.3) 
17 (5.7) 
11 (3.0) 
 
22 (86.4) 
3 (10.2) 
1 (3.4) 
 
201 (94.2) 
7 (1.5) 
11 (4.3) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
1219 (17.7) 
1583 (24.8) 
2801 (38.5) 
1539 (19.0) 
 
33 (10.5) 
65 (29.0) 
58 (20.4) 
111 (40.1) 
 
2 (12.4) 
11 (50.4) 
7 (28.6) 
6 (8.5) 
 
27 (14.5) 
53 (29.9) 
58 (29.0) 
81 (26.6) 
Other Health Conditions 2433 (32.3) 71 (27.7) 5 (8.2) 53 (19.1) 
Energy Therapies  483 (7.0) 45 (18.3) 6 (21.5) 47 (21.4) 
Acupuncture 165 (2.1) 21 (8.3) 2 (12.7) 10 (4.7) 
Mind-Body Therapies 352 (5.0) 34 (13.1) 3 (12.6) 31 (14.0) 
Chiropractic/ Osteopathic Therapy 758 (11.0) 56 (22.5) 5 (23.2) 55 (24.8) 
*This table presents unweighted frequencies and weighted column percentages. 
Table 4 presents past 12 month glucosamine and/or chondroitin use among persons with 
unspecified arthritis. Approximately 3.7% of persons with unspecified arthritis were glucosamine 
users, 0.5% were chondroitin users, and 3.8% were both glucosamine and chondroitin users. 
Similar to among persons with any arthritis, among persons with unspecified arthritis, 
glucosamine and both glucosamine and chondroitin users were more likely to be women (60.7% 
and 61.9% respectively) than men. Men were more likely to be chondroitin users (57.3). Persons 
ages 56-70 years of age made up a large proportion of supplement used (49.1% glucosamine use, 
45.2% chondroitin use, and 60.7% both glucosamine and chondroitin use). More than half 
(54.9%) of the proportion of chondroitin users were from the Midwest. 
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Table 4: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult 
Ages 18+ with Unspecified Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Unspecified Arthritis 
n= 6016 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 5590 (92.0) 207 (3.7) 24 (0.5) 195 (3.8) 
Sex 
     Men 
     Women 
 
2087 (41.2) 
3503 (58.8) 
 
74 (39.3) 
133 (60.7) 
 
10 (57.3) 
14 (42.7) 
 
76 (38.1) 
119 (61.9) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     >85 years old 
 
418 (8.5) 
1243 (25.3) 
2207 (39.5) 
1332 (21.2) 
390 (5.5) 
 
11 (6.1) 
52 (26.0) 
101 (49.1) 
38 (16.6) 
5 (2.2) 
 
0 (0.0) 
6 (33.2) 
11 (45.2) 
6 (17.8) 
1 (3.7) 
 
10 (6.9) 
36 (18.2) 
115 (60.7) 
30 (12.6) 
4 (1.6) 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
3909 (77.7) 
907 (11.1) 
574 (8.2) 
170 (2.5) 
30 (0.4) 
 
161 (84.1) 
23 (9.5) 
12 (4.1) 
9 (2.2) 
2 (0.1) 
 
22 (93.2) 
1 (3.6) 
1 (3.2) 
0 (0.0) 
0 (0.0) 
 
171 (91.8) 
14 (4.5) 
8 (3.1) 
1 (0.2) 
1 (0.5) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1524 (26.0) 
1928 (35.2) 
2138 (38.7) 
 
59 (27.9) 
71 (35.4) 
77 (36.6) 
 
6 (20.3) 
9 (42.1) 
9 (37.5) 
 
38 (18.4) 
72 (32.5) 
85 (49.1) 
Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
812 (9.6) 
163 (2.4) 
1264 (21.5) 
1136 (20.8) 
684 (14.2) 
883 (17.9) 
648 (13.5) 
 
5 (0.6) 
1 (0.1) 
36 (15.5) 
48 (22.5) 
32 (15.6) 
41 (22.2) 
44 (23.5) 
 
1 (2.0) 
0 (0.0) 
2 (8.8) 
5 (18.7) 
5 (24.1) 
4 (20.6) 
7 (25.8) 
 
4 (2.0) 
1 (0.7) 
23 (12.3) 
33 (14.1) 
37 (21.9) 
52 (27.5) 
45 (21.5) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
4137 (78.6) 
947 (12.5) 
506 (9.0) 
 
186 (93.4) 
10 (2.8) 
11 (3.8) 
 
21 (93.1) 
2 (3.2) 
1 (3.7) 
 
179 (93.9) 
6 (1.6) 
10 (4.6) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
967 (17.9) 
1269 (25.4) 
2167 (38.3) 
1187 (18.4) 
 
25 (10.8) 
56 (32.2) 
38 (16.6) 
88 (40.4) 
 
2 (13.5) 
11 (54.9) 
6 (23.2) 
5 (8.4) 
 
24 (14.2) 
48 (30.1) 
54 (29.9) 
69 (15.9) 
Other Health Conditions 1904 (32.7) 55 (26.7) 4 (8.1) 47 (20.2) 
Energy Therapies  372 (7.1) 37 (18.5) 6 (23.4) 41 (20.5) 
Acupuncture 131 (2.1) 16 (7.6) 2 (13.9) 7 (2.9) 
Mind-Body Therapies 258 (4.7) 27 (11.0) 2 (5.8) 27 (13.4) 
Chiropractic/ Osteopathic Therapy 604 (11.4) 47 (23.6) 5 (25.3) 48 (23.0) 
*This table presents unweighted frequencies and weighted column percentages. 
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Table 5 presents past 12 month glucosamine and/or chondroitin use among persons with 
rheumatoid arthritis. Approximately 2.4% of persons with rheumatoid arthritis used glucosamine 
while 0.3% used chondroitin, and 2.1% used both glucosamine and chondroitin. The majority of 
glucosamine and both glucosamine and chondroitin use were women (59.3% and 58.0% 
respectively) however; men made up 94.0% of chondroitin use. Persons 40-55 years old made up 
85.1% of chondroitin use. Obese (BMI >30.0) individuals had the highest proportion of 
glucosamine and chondroitin use (42.9% and 94.0% respectively). While glucosamine use and 
both glucosamine and chondroitin use were most common among persons above poverty level 
(83.3% and 100.0% respectively), persons below poverty level made up the highest proportion of 
chondroitin use (85.1%). 
Table 5: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult 
Ages 18+ with Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Rheumatoid Arthritis 
n= 898 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 845 (95.2) 32 (2.4) 13 (0.3) 18 (2.1) 
Sex 
     Men 
     Women 
 
263 (34.2) 
582 (65.8) 
 
10 (40.7) 
22 (59.3) 
 
2 (94.0) 
1 (6.0) 
 
9 (42.0) 
9 (58.0) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     >85 years old 
 
81 (11.7) 
233 (31.1) 
323 (35.8) 
159 (16.8) 
49 (4.6) 
 
4 (23.4) 
8 (23.1) 
13 (40.2) 
6 (12.3) 
1 (1.0) 
 
0 (0.0) 
1 (85.1) 
1 (6.0) 
1 (8.9) 
0 (0.0) 
 
2 (9.6) 
5 (44.1) 
8 (37.8) 
2 (7.6) 
1 (1.0) 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
495 (67.0) 
199 (17.0) 
128 (13.4) 
13 (1.5) 
10 (1.0) 
 
21 (64.5) 
5 (16.6) 
4 (15.3) 
1 (1.1) 
1 (2.5) 
 
2 (91.1) 
0 (0.0) 
1 (8.9) 
0 (0.0) 
0 (0.0) 
 
14 (75.7) 
1 (2.8) 
1 (5.4) 
2 (16.1) 
0 (0.0) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
233 (26.7) 
257 (30.7) 
355 (42.6) 
 
7 (21.6) 
13 (35.5) 
12 (42.9) 
 
0 (0.0) 
1 (6.0) 
2 (94.0) 
 
6 (39.0) 
6 (33.2) 
6 (27.7) 
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Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
123 (10.1) 
36 (3.6) 
208 (23.4) 
171 (20.9) 
129 (18.0) 
105 (12.8) 
73 (11.0) 
 
3 (12.8) 
1 (1.2) 
5 (14.2) 
12 (29.1) 
4 (17.6) 
4 (14.9) 
3 (10.4) 
 
0 (0.0) 
0 (0.0) 
1 (8.9) 
0 (0.0) 
1 (85.1) 
0 (0.0) 
1 (6.0) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
2 (8.6) 
3 (31.9) 
4 (26.3) 
9 (33.3) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
578 (76.1) 
201 (16.0) 
66 (7.9) 
 
28 (83.3) 
4 (16.7) 
0 (0.0) 
 
2 (14.9) 
1 (85.1) 
0 (0.0) 
 
18 (100.0) 
0 (0.0) 
0 (0.0) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
151 (19.0) 
164 (21.4) 
351 (39.4) 
179 (20.2) 
 
4 (7.7) 
4 (20.8) 
11 (39.4) 
13 (32.1) 
 
0 (0.0) 
0 (0.0) 
1 (85.1) 
2 (14.9) 
 
2 (6.3) 
6 (52.6) 
1 (3.7) 
9 (29.3) 
Other Health Conditions 321 (35.1) 9 (20.7) 2 (14.9) 4 (12.1) 
Energy Therapies  49 (5.3) 3 (12.1) 1 (6.0) 5 (40.6) 
Acupuncture 19 (1.9) 2 (7.6) 0 (0.0) 3 (29.5) 
Mind-Body Therapies 40 (4.6) 3 (9.2) 1 (85.1) 2 (25.7) 
Chiropractic/ Osteopathic Therapy 63 (7.7) 7 (22.7) 0 (0.0) 8 (53.5) 
*This table presents unweighted frequencies and weighted column percentages. 
 
Table 6 presents past 30 day glucosamine and/or chondroitin use among persons with any 
arthritis. Approximately 5.1% of persons with any arthritis used glucosamine, 0.6% used 
chondroitin, and 0.4% used both glucosamine and chondroitin within the past 30 days. As 
presented in Table 6, women made up the majority of all past 30 day supplement use (59.3% 
glucosamine, 76.6% chondroitin, and 63.4% both glucosamine and chondroitin). Persons 56 to 
70 years old had the highest proportion of all past 30 day supplement use (55.7% glucosamine, 
57.7% chondroitin, and 39.2% both glucosamine and chondroitin). White people also made up 
the majority of all past 30 day supplement use (90.3% glucosamine, 81.9% chondroitin, and 
72.4% both glucosamine and chondroitin). Persons above poverty level also made up the 
majority of all past 30 day supplement use (92.1% glucosamine, 80.2% chondroitin, and 96.7% 
both glucosamine and chondroitin). 
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Table 6: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages 
18+ with Any Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Any Arthritis 
n= 7654 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 7244  (94.0) 339 (5.1) 45 (0.6) 26 (0.4) 
Sex 
     Men 
     Women 
 
2738 (41.7) 
4506 (58.3) 
 
132 (40.7) 
207 (59.3) 
 
11 (23.4) 
34 (76.6) 
 
8 (36.6) 
18 (63.4) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     >85 years old 
 
640 (10.0) 
1734 (27.0) 
2821 (38.5) 
1593 (19.5) 
456 (5.0) 
 
13 (5.0) 
72 (20.9) 
177 (55.7) 
67 (16.5) 
10 (1.9) 
 
6 (9.6) 
12 (21.0) 
21 (57.7) 
6 (11.7) 
0 (0.0) 
 
3 (11.1) 
8 (28.6) 
11 (39.2) 
3 (18.4) 
1 (2.7) 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or  
     Alaskan Native 
     Asian 
 
5012 (76.8) 
1213 (11.6) 
751 (8.5) 
222 (2.5) 
 
46 (0.5) 
 
282 (90.3) 
22 (4.1) 
21 (4.0) 
11 (1.3) 
 
3 (0.2) 
 
33 (81.9) 
7 (7.6) 
5 (10.5) 
0 (0.0) 
 
0 (0.0) 
 
19 (72.4) 
6 (25.4) 
0 (0.0) 
1 (2.1) 
 
0 (0.0) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1948 (25.5) 
2476 (35.1) 
2820 (39.4) 
 
84 (26.1) 
127 (34.6) 
128 (39.3) 
 
11 (33.3) 
15 (23.6) 
19 (43.1) 
 
8 (19.0) 
11 (55.7) 
7 (25.3) 
Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
973 (8.7) 
216 (2.5) 
1636 (21.1) 
1474 (20.8) 
930 (15.1) 
1156 (17.7) 
859 (14.0) 
 
7 (1.2) 
2 (0.5) 
53 (15.6) 
65 (16.8) 
62 (20.5) 
68 (22.2) 
82 (23.2) 
 
3 (4.9) 
3 (3.5) 
5 (12.9) 
9 (21.2) 
6 (13.5) 
8 (20.0) 
11 (23.8) 
 
3 (6.7) 
0 (0.0) 
4 (17.8) 
6 (17.8) 
0 (0.0) 
10 (32.0) 
3 (25.8) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
5388 (79.0) 
1230 (12.5) 
626 (8.5) 
 
308 (92.1) 
14 (3.6) 
17 (4.3) 
 
33 (80.2) 
9 (15.0) 
3 (4.8) 
 
24 (96.7) 
1 (0.6) 
1 (2.7) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
1231 (17.5) 
1612 (25.0) 
2822 (38.4) 
1579 (19.1) 
 
44 (14.5) 
83 (30.8) 
80 (22.3) 
132 (32.5) 
 
2 (6.5) 
12 (34.9) 
15 (31.0) 
16 (27.6) 
 
4 (9.1) 
5 (12.9) 
7 (29.0) 
10 (49.1) 
Other Health Conditions 2459 (32.2) 86 (22.9) 13 (20.2) 4 (28.6) 
Energy Therapies  509 (7.3) 52 (15.5) 11 (34.7) 9 (47.4) 
Acupuncture 171 (2.2) 18 (5.9) 5 (9.3) 4 (16.7) 
Mind-Body Therapies 365 (5.2) 40 (11.6) 9 (21.2) 6 (28.7) 
Chiropractic/ Osteopathic Therapy 777 (11.2) 75 (23.5) 13 (22.9) 9 (35.8) 
*This table presents unweighted frequencies and weighted column percentages. 
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Table 7 presents past 30 day glucosamine and/or chondroitin use among persons with 
unspecified arthritis. Approximately 5.5% of persons with unspecified arthritis had past 30 day 
use of glucosamine, 0.5% chondroitin, and 0.4% both glucosamine and chondroitin. Women 
made up the majority of all supplement use (62.4% glucosamine, 69.7% chondroitin, and 56.8% 
both glucosamine and chondroitin). Persons age 56 to 70 years old reported the highest 
proportion of past 30 day supplement use (57.9% glucosamine, 57.1% chondroitin, 33.0% both 
glucosamine and chondroitin). Supplement use was most common among white persons with 
unspecified arthritis (90.9% glucosamine, 78.3% chondroitin, and 67.2% both glucosamine and 
chondroitin).  Persons above poverty level also had the highest proportion of all supplement use 
(93.0% glucosamine, 76.6% chondroitin, and 95.5% both glucosamine and chondroitin). Persons 
with unspecified arthritis in the Northeast had the lowest proportion of any supplement use 
(14.7% glucosamine, 2.0% chondroitin, and 5.3% both glucosamine and chondroitin). 
Table 7: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages 
18+ with Unspecified Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Unspecified Arthritis 
n= 6016 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 5675 (93.5) 287 (5.5) 35 (0.5) 19 (0.4) 
Sex 
     Men 
     Women 
 
2125 (41.4) 
3550 (58.6) 
 
106 (37.6) 
181 (62.4) 
 
10 (30.3) 
25 (69.7) 
 
6 (43.3) 
13 (56.8) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     ≥ 85 years old 
 
422 (8.5) 
1271 (25.5) 
2249 (39.6) 
1341 (20.9) 
392 (5.5) 
 
9 (4.9) 
56 (18.3) 
158 (57.9) 
57 (16.9) 
7 (2.0) 
 
6 (12.7) 
7 (15.5) 
17 (57.1) 
5 (14.8) 
0 (0.0) 
 
2 (10.0) 
3 (26.6) 
10 (33.0) 
3 (24.7) 
1 (3.7) 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
3984 (77.9) 
915 (11.1) 
575 (8.1) 
170 (2.4) 
31 (0.5) 
 
242 (90.9) 
19 (4.3) 
15 (3.3) 
9 (1.4) 
2 (0.1) 
 
24 (78.3) 
6 (7.7) 
5 (14.0) 
0 (0.0) 
0 (0.0) 
 
13 (67.2) 
5 (30.0) 
0 (0.0) 
1 (2.8) 
0 (0.0) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
 
1543 (25.8) 
1954 (35.2) 
 
69 (24.3) 
104 (34.6) 
 
9 (37.4) 
14 (30.5) 
 
6 (21.3) 
8 (49.9) 
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    ≥ 25.0 2178 (39.0) 114 (41.1) 12 (32.1) 5 (28.8) 
Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
811 (9.4) 
162 (2.3) 
1275 (21.3) 
1157 (20.8) 
698 (14.3) 
905 (18.0) 
667 (13.7) 
 
6 (1.3) 
1 (0.5) 
44 (14.9) 
51 (16.7) 
55 (19.5) 
63 (24.8) 
67 (22.2) 
 
3 (6.4) 
2 (1.9) 
3 (6.7) 
8 (27.4) 
5 (11.2) 
6 (19.5) 
8 (26.7) 
 
2 (6.3) 
0 (0.0) 
3 (22.3) 
6 (23.9) 
0 (0.0) 
6 (30.4) 
      2 (17.1) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
4221 (80.0) 
946 (12.2) 
508 (8.8) 
 
261 (93.0) 
10 (2.2) 
16 (4.8) 
 
24 (76.6) 
8 (17.1) 
3 (6.3) 
 
17 (95.5) 
1 (0.8) 
1 (3.7) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
978 (17.8) 
1297 (25.6) 
2182 (38.1) 
1218 (18.6) 
 
37 (14.7) 
76 (32.6) 
65 (21.4) 
109 (31.4) 
 
1 (2.0) 
8 (30.5) 
12 (32.0) 
14 (35.5) 
 
2 (5.3) 
3 (14.0) 
6 (37.4) 
8 (43.3) 
Other Health Conditions 1927 (32.5) 72 (22.8) 9 (20.1) 2 (19.3) 
Energy Therapies  396 (7.4) 45 (15.4) 8 (38.6) 7 (41.1) 
Acupuncture 133 (2.1) 15 (5.1) 5 (12.3) 3 (17.5) 
Mind-Body Therapies 270 (4.9) 32 (9.4) 7 (21.0) 5 (21.0) 
Chiropractic/ Osteopathic Therapy 621 (11.5) 68 (24.3) 9 (19.1) 6 (22.8) 
*This table presents unweighted frequencies and weighted column percentages. 
 
Table 8 presents past 30 day glucosamine and/or chondroitin use among persons with 
rheumatoid arthritis. Approximately 2.9% of persons with rheumatoid arthritis had past 30 day 
use of glucosamine, 0.7% chondroitin, and 0.5% both glucosamine and chondroitin. Persons 18 
to 39 years old reported the largest proportion of both glucosamine and chondroitin use. Persons 
56 to 70 years old reported the largest proportion of glucosamine use (42.9%) and chondroitin 
use (85.8%). Persons above poverty level also had the highest proportion of all supplement use 
(95.7% glucosamine, 100.0% chondroitin, and 100.0 both glucosamine and chondroitin). A large 
proportion of persons that reported past 30 day chondroitin use were from the Midwest (60.9%). 
Nearly half of the proportion of persons with rheumatoid arthritis that reported use of 
chiropractic/osteopathic therapy reported past 30 day use of chondroitin (46.7%) and both 
glucosamine and chondroitin (52.9%). 
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Table 8: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages 18+ with 
Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)  
Sample Adult with Rheumatoid Arthritis 
n= 898 
 
Characteristics 
No Supplemental Use 
n (% ) 
Glucosamine Only 
n (%) 
Chondroitin Only 
n (%) 
Both 
n (%) 
Total 856 (96.0) 34 (2.9) 3 (0.7) 5 (0.5) 
Sex 
     Men 
     Women 
 
270 (34.9) 
586 (65.1) 
 
12 (29.7) 
22 (70.2) 
 
0 (0.0) 
3 (100.0) 
 
2 (65.2) 
3 (34.8) 
Age 
     18-39 years old 
     40-55 years old 
     56-70 years old 
     71-84 years old 
     ≥ 85 years old 
 
83 (11.9) 
236 (31.4) 
328 (35.4) 
160 (16.7) 
49 (4.6) 
 
2 (4.6) 
8 (35.4) 
14 (42.9) 
8 (15.7) 
2 (1.5) 
 
0 (0.0) 
1 (14.2) 
2 (85.8) 
0 (0.0) 
0 (0.0) 
 
2 (65.2) 
2 (22.1) 
1 (12.7) 
0 (0.0) 
0 (0.0) 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
502 (66.8) 
201 (17.0) 
129 (13.3) 
14 (1.8) 
10 (1.0) 
 
24 (74.6) 
2 (4.7) 
5 (16.4) 
2 (2.2) 
1 (2.0) 
 
2 (85.8) 
1 (14.2) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
4 (87.3) 
1 (12.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
234 (26.5) 
262 (31.1) 
360 (42.4) 
 
9 (33.4) 
13 (26.6) 
12 (40.0) 
 
1 (39.1) 
0 (0.0) 
2 (60.9) 
 
2 (22.1) 
2 (38.9) 
1 (39.0) 
Education 
    Did Not Complete High School 
    GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
124 (10.3) 
36 (3.6) 
208 (23.0) 
174 (20.9) 
131 (18.3) 
107 (12.9) 
76 (11.1) 
 
1 (1.2) 
1 (1.0) 
3 (8.2) 
10 (23.6) 
6 (33.0) 
3 (5.8) 
10 (27.3) 
 
0 (0.0) 
0 (0.0) 
1 (46.7) 
1 (14.2) 
0 (0.0) 
1 (39.1) 
0 (0.0) 
 
1 (14.0) 
0 (0.0) 
2 (20.8) 
0 (0.0) 
0 (0.0) 
2 (65.2) 
0 (0.0) 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
586 (75.7) 
204 (16.4) 
66 (7.9) 
 
32 (95.7) 
2 (4.3) 
0 (0.0) 
 
3 (100.0) 
0 (0.0) 
0 (0.0) 
 
5 (100.0) 
0 (0.0) 
0 (0.0) 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
151 (18.8) 
165 (21.3) 
353 (39.3) 
187 (20.6) 
 
5 (14.6) 
7 (37.6) 
7 (19.5) 
15 (28.3) 
 
0 (0.0) 
2 (60.9) 
1 (39.1) 
0 (0.0) 
 
1 (14.0) 
0 (0.0) 
3 (59.9) 
1 (26.1) 
Other Health Conditions 325 (35.0) 10 (19.4) 0 (0.0) 1 (8.1) 
Energy Therapies  51 (5.3) 5 (26.0) 1 (39.1) 1 (26.1) 
Acupuncture 20 (2.0) 2 (17.4) 1 (14.2) 1 (26.1) 
Mind-Body Therapies 42 (4.9) 3 (22.0) 0 (0.0) 1 (12.7) 
Chiropractic/ Osteopathic Therapy 69 (8.1) 5 (23.5) 1 (46.7) 3 (52.9) 
*This table presents unweighted frequencies and weighted column percentages. 
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BIVARIATE ANALYSES 
 Table 9 presents odds ratios, 95% Confidence intervals (95% CI), and p-values for 
selected characteristics and self-reported past 12 month improved health among persons with any 
arthritis, unspecified arthritis, and rheumatoid arthritis. Age, sex, and region were demographic 
characteristics that yielded statistically significant associations with self-reported past 12 month 
improved health among persons with any arthritis. When compared to persons 18 to 39 years old, 
persons 40 to 55 years old were 0.6 times likely to report improved health (OR= 0.6; p= 0.04), 
persons 71 to 84 years old were 0.4 times likely to report improved health (OR= 0.4; p= 0.01), 
and persons 85 years old and older were 0.2 times likely to report improved health (OR= 0.2; p= 
<0.01) among persons with any arthritis. Men were 0.8 times likely to report improved health 
when compared to women (OR= 0.8; p= 0.02). Persons in the West were 1.3 times likely to 
report improved health when compared to persons in the Northeast (OR=1.3; p= 0.01). 
 All other observed CAM therapies (acupuncture, energy, chiropractic/osteopathic, and 
mind-body therapies), were shown to be associated with self-reported past 12 month improved 
health among persons with any arthritis. Persons that saw an acupuncturist one of more times 
within the 12 months prior to survey administration were 1.9 times likely to report improved 
health when compared to persons that has not seen an acupuncturist (OR= 1.9; p= <0.01). 
Persons that engaged in energy therapies one or more times within the 12 months prior to taking 
the survey were 2.2 times likely to report improved health when compared to persons that never 
engaged in energy therapy (OR= 2.2; p= <0.01) among persons with any arthritis. Persons that 
engaged in a mind-body therapy one or more times within the 12 months prior to the 
administration of the survey were also 2.2 times likely to report improved health when compared 
to persons that never engaged in an energy therapy (OR=2.2; p= <0.01). Persons that saw a 
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chiropractor one of more times within the 12 months prior to survey administration were 1.4 
times likely to report improved health when compared to persons that did not (OR= 1.4; p= 
<0.01). 
 Sex, age, BMI, and education were demographic characteristics that yielded statistically 
significant associations with self-reported past 12 month improved health among persons with 
unspecified arthritis, as seen in Table 9. Men were 0.8 times likely to report improved health 
than women (OR= 0.8; p= 0.02). When compared to persons 18 to 39 years old, persons 71 to 84 
years old were 0.3 times likely to report improved health (OR= 0.3; p= <0.01) and persons 85 
years and older were 0.2 times likely to report improved health (OR= 0.2; p= <0.01). Obese 
(BMI ≥ 30) persons with unspecified arthritis were 1.3 times likely to report improved health 
than persons that were either underweight or normal weight (OR= 1.3; p= 0.01). When compared 
to persons that did not complete high school, persons with a high school diploma were 0.9 times 
likely to report improved health (OR= 0.9; p= <0.01), persons with some college were 1.5 times 
likely to report improved health (OR= 1.5; p= 0.02), and persons with an associate’s degree 1.6 
times likely to report improved health (OR= 1.6; p= 0.04). 
As can be seen in Table 9, all other observed CAM therapies (acupuncture, energy, 
chiropractic/osteopathic, and mind-body therapies) were shown to be associated with self-
reported past 12 month improved health among persons with unspecified arthritis. Persons who 
saw an acupuncturist one of more times within the 12 months prior to survey administration were 
1.8 times likely to report improved health when compared to persons that has not seen an 
acupuncturist (OR= 1.8; p= 0.01). Persons that engaged in energy therapies one or more times 
within the 12 months prior to taking the survey were 2.1 times likely to report improved health 
when compared to persons that never engaged in an energy therapy during this period (OR= 2.1; 
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p= <0.01). Persons that engaged in mind-body therapy one or more times within the 12 months 
prior to the administration of the survey were also 2.2 times likely to report improved health 
when compared to persons that never engaged in a mind-body therapy during this period 
(OR=2.2; p= <0.01). Persons that saw a chiropractor one of more times within the 12 months 
prior to survey administration were 1.3 times likely to report improved health when compared to 
persons that did not (OR= 1.3; p= 0.01). 
While no demographic characteristics yielded statistically significant associations with 
self-reported past 12 month improved health among persons with rheumatoid arthritis, all other 
observed CAM therapies (acupuncture, energy, chiropractic/ osteopathic, and mind-body 
therapies) did, as seen in Table 9. Persons who saw an acupuncturist one of more times within 
the 12 months prior to survey administration were 4.6 times likely to report improved health 
when compared to persons that had not (OR= 4.6; p= <0.01). Persons that engaged in an energy 
therapy one or more times within the 12 months prior to taking the survey were 2.7 times likely 
to report improved health when compared to persons that had not (OR= 2.7; p= 0.01). Persons 
that engaged in a mind-body therapy one or more times within the 12 months prior to the 
administration of the survey were also 2.7 times likely to report improved health when compared 
to persons that never engaged in an mind-body therapy during this period (OR=2.7; p= <0.01). 
Persons that saw a chiropractor one of more times within the 12 months prior to survey 
administration were 2.5 times likely to report improved health when compared to persons that 
did not (OR= 2.5; p= <0.01). 
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Table 9: Bivariate Analysis of Selected Characteristics and Reports of Improved Health Over a 12 Month Period among Persons 
with Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS) 
Self-Reported Improved Health over a 12-Month Period 
 
Characteristics 
Any Arthritis 
n= 7654 
Unspecified Arthritis 
n= 6016 
Rheumatoid Arthritis 
n= 898 
  OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
No Supplement Use 
Glucosamine Only 
Chondroitin Only 
Glucosamine and Chondroitin 
1.0 (referent) 
1.4 (1.0-1.9) 
0.7 (0.3-1.7) 
1.1 (0.7-1.7) 
 
0.07 
0.28 
0.67 
1.0 (referent) 
1.2 (0.8-1.8) 
0.7 (0.3-1.9) 
1.1 (0.7-1.7) 
 
0.40 
0.43 
0.65 
1.0 (referent) 
1.5 (0.7-3.4) 
0.4 (0.1-2.8) 
2.7 (0.8-9.5) 
 
0.47 
0.17 
0.11 
Sex    
    Women 
    Men 
 
1.0 (referent) 
0.8 (0.7-1.0) 
 
 
0.02 
 
1.0 (referent) 
0.8 (0.7-1.0) 
 
 
0.02 
 
1.0 (referent) 
1.0 (0.6-1.5) 
 
 
0.86 
Age 
    18-39 years old 
    40-55 years old 
    56-70 years old 
    71-84 years old 
    >85 years old 
 
1.0 (referent) 
0.6 (0.4-0.7) 
0.5 (0.4-0.7) 
0.4 (0.3-0.5) 
0.2 (0.1-0.4) 
 
 
0.04 
0.27 
0.01 
<0.01 
 
1.0 (referent) 
0.5 (0.4-0.7) 
0.5 (0.4-0.7) 
0.3 (0.2-0.5) 
0.2 (0.1-0.3) 
 
 
0.10 
0.21 
<0.01 
<0.01 
 
1.0 (referent) 
0.5 (0.2-1.0) 
0.5 (0.2-1.0) 
0.4 (0.2-0.9) 
0.1 (0.0-0.3) 
 
 
0.37 
0.23 
0.59 
<0.01 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
1.0 (referent) 
1.1 (0.9-1.3) 
1.3 (1.0-1.6) 
1.1 (0.7-1.7) 
1.0 (0.4-2.8) 
 
 
0.98 
0.28 
0.99 
0.89 
 
1.0 (referent) 
1.1 (0.8-1.3) 
1.3 (1.0-1.6) 
1.3 (0.8-2.1) 
0.8 (0.2-3.5) 
 
 
0.98 
0.38 
0.50 
0.66 
 
1.0 (referent) 
1.2 (0.8-1.8) 
1.1 (0.7-1.8) 
0.4 (0.1-1.7) 
2.8 (1.0-7.4) 
 
 
0.59 
0.79 
0.09 
0.03 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1.0 (referent) 
1.0 (0.8-1.2) 
1.1 (0.9-1.3) 
 
 
0.29 
0.10 
 
1.0 (referent) 
1.0 (0.8-1.3) 
1.3 (1.0-1.5) 
 
 
0.42 
0.01 
 
1.0 (referent) 
0.6 (0.4-1.0) 
0.5 (0.3-0.9) 
 
 
0.25 
0.06 
Education 
    Did Not Complete  High School 
     GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
1.0 (referent) 
0.9 (0.5-1.5) 
0.9 (0.7-1.3) 
1.4 (1.1-1.9) 
1.6 (1.2-2.1) 
1.4 (1.0-1.8) 
1.5 (1.1-2.0) 
 
 
0.13 
<0.01 
0.05 
<0.01 
0.15 
0.04 
 
1.0 (referent) 
1.0 (0.6-1.9) 
0.9 (0.7-1.3) 
1.5 (1.1-2.1) 
1.6 (1.1-2.2) 
1.3 (1.0-1.9) 
1.5 (1.1-2.0) 
 
 
0.44 
<0.01 
0.02 
0.04 
0.39 
0.08 
 
1.0 (referent) 
0.6 (0.2-2.0) 
0.9 (0.4-1.7) 
1.0 (0.5-2.0) 
1.5 (0.8-2.7) 
1.4 (0.5-3.4) 
1.5 (0.7-2.9) 
 
 
0.23 
0.32 
0.85 
0.07 
0.45 
0.21 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
1.0 (referent) 
0.9 (0.7-1.1) 
0.8 (0.6-1.1) 
 
 
0.28 
0.30 
 
1.0 (referent) 
1.0 (0.8-1.3) 
0.9 (0.6-1.2) 
 
 
0.58 
0.38 
 
1.0 (referent) 
0.6 (0.4-1.0) 
0.7 (0.3-1.3) 
 
 
0.32 
0.60 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
1.0 (referent) 
1.1 (0.8-1.4) 
1.0 (0.8-1.2) 
1.3 (1.0-1.6) 
 
 
0.91 
0.09 
0.01 
 
1.0 (referent) 
1.1 (0.8-1.4) 
1.0 (0.7-1.2) 
1.2 (0.9-1.5) 
 
 
0.71 
0.12 
0.09 
 
1.0 (referent) 
1.1 (0.6-1.9) 
0.9 (0.5-1.6) 
1.5 (1.0-2.5) 
 
 
0.83 
0.25 
0.02 
No Other Health Conditions 
Other Health Conditions  
1.0 (referent) 
1.0 (0.8-1.2) 
 
0.99 
1.0 (referent) 
1.0 (0.9-1.2) 
 
0.87 
1.0 (referent) 
0.9 (0.6-1.3) 
 
0.42 
No Energy Therapies  
Energy Therapies 
1.0 (referent) 
2.2 (1.7-2.8) 
 
<0.01 
1.0 (referent) 
2.1 (1.6-2.8) 
 
<0.01 
1.0 (referent) 
2.7 (1.4-5.1) 
 
<0.01 
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No Acupuncture 
Acupuncture 
1.0 (referent) 
1.9 (1.3-2.8) 
 
<0.01 
1.0 (referent) 
1.8 (1.2-2.8) 
 
0.01 
1.0 (referent) 
4.6 (1.8-11.5) 
 
<0.01 
No Mind-Body Therapies 
Mind-Body Therapies 
1.0 (referent) 
2.2 (1.7-3.0) 
 
<0.01 
1.0 (referent) 
2.2 (1.6-3.2) 
 
<0.01 
1.0 (referent) 
2.7 (1.3-5.5) 
 
0.01 
No Chiropractic/ Osteopathic Therapy 
Chiropractic/ Osteopathic Therapy 
1.0 (referent) 
1.4 (1.2-1.7) 
 
<0.01 
1.0 (referent) 
1.3 (1.1-1.7) 
 
0.01 
1.0 (referent) 
2.5 (1.4-4.4) 
 
<0.01 
*Estimates presented were found using a logistic regression. 
 Table 10 presents odds ratios, 95% Confidence intervals (95% CI), and p-values for 
selected characteristics and self-reported joint pain, aching, and stiffness within the past 30 days 
prior to taking the survey among persons with any arthritis, unspecified arthritis, and rheumatoid 
arthritis. Sex, age, race, BMI, poverty level, other health conditions (diabetes and/or heart 
condition), and chiropractic/osteopathic therapy were characteristics that yielded statistically 
significant associations with self-reported past 30 day joint pain, aching, and stiffness among 
persons with any arthritis. Men were 0.9 times likely to report past 30 day joint pain, aching, and 
stiffness than women (OR= 0.9; p= 0.02) among persons with any arthritis. Persons 56 to 70 
years old were 1.5 times likely to report past 30 day joint pain, aching, and stiffness than persons 
18 to 39 years old (OR= 1.5; p= <0.01) among persons with any arthritis. When compared to 
white persons with any arthritis, Black/African Americans were 1.2 times likely to report past 30 
day joint pain, aching, and stiffness  (OR= 1.2; p= 0.04) and American Indian or Alaskan Native 
were 0.7 times likely to report past 30 day joint pain, aching, and stiffness (OR= 0.7; p= 0.03). 
Obese persons (BMI ≥ 30) were 1.8 times likely to report past 30 day joint pain, aching, and 
stiffness than persons either underweight or normal weight (BMI< 25) (OR= 1.8; p= <0.01). 
Persons below the poverty line were 1.3 time likely to report past 30 day joint pain, aching, and 
stiffness than persons above the poverty line (OR= 1.3; p= 0.04). Persons with other health 
conditions (diabetes and heart conditions) were 1.4 times likely to report past 30 day joint pain, 
aching, and stiffness than persons without other health conditions (OR= 1.4; p= <0.01). Persons 
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that saw a chiropractor one of more times within the 12 months prior to survey administration 
were 1.3 times likely to report past 30 day joint pain, aching, and stiffness when compared to 
persons that did not (OR= 2.5; p= <0.01). 
 Age, BMI, poverty level, region, other health conditions (diabetes and/or heart 
condition), mind-body therapies, and chiropractic/osteopathic therapy were characteristics that 
yielded statistically significant associations with self-reported past 30 day joint pain, aching, and 
stiffness among persons with unspecified arthritis, as seen in Table 10. Persons 56 to 70 years of 
age were 1.4 times likely to report past 30 day joint pain, aching, and stiffness than persons 18 to 
39 years old (OR= 1.1; p= <0.01). Obese persons (BMI ≥ 30) were 2.0 times likely to report 
BMI past 30 day joint pain, aching, and stiffness than persons underweight and normal weight 
(BMI < 25) (OR= 2.0; p= <0.01). Persons below poverty level were 1.3 times likely to report 
past 30 day joint pain, aching, and stiffness than persons above poverty level (OR= 1.3; p= 0.03). 
Persons in the South were 1.5 times likely to report past 30 day joint pain, aching, and stiffness 
than persons in the Northeast region (OR= 1.5; p= 0.01). Persons with other health conditions 
(diabetes and heart conditions) were 1.6 times likely to report past 30 day joint pain, aching, and 
stiffness than persons without other health conditions (OR= 1.6; p= <0.01).  Persons that 
reported past 12 month use of mind-body therapy were 1.4 times likely to past 30 day joint pain, 
aching, and stiffness than persons that never engaged in mind-body therapy (OR=1.4; p= 0.02). 
Persons that saw a chiropractor one of more times within the 12 months prior to survey 
administration were 1.3 times likely to report past 30 day joint pain, aching, and stiffness when 
compared to persons that did not (OR= 1.3; p= 0.03). 
As shown in Table 10, only poverty level and mind-body therapies were characteristics 
that yielded statistically significant associations with self-reported past 30 day joint pain, aching, 
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and stiffness among persons with unspecified arthritis, as seen in Table 10. When compared to 
persons above the poverty level, persons below were 2.6 times likely to report past 30 day joint 
pain, aching, and stiffness (OR= 2.6; p= <0.01), and persons whom poverty level is unknown 
were 0.8 time likely to report past 30 day joint pain, aching, and stiffness (OR= 0.8; p= 0.03). 
Finally, persons that engaged in mind-body therapy one or more times within the 12 months 
prior to the administration of the survey were 0.4 times likely to report past 30 day joint pain, 
aching, and stiffness when compared to persons that never engaged in mind-body therapy (OR= 
0.4; p= 0.03). 
Table 10: Bivariate Analysis of Selected Characteristics and Reports of Joint Pain, Aching, or Stiffness in or around a Joint Over the Past 30 Days 
among Persons with Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS) 
Self-Reported Joint Pain in Past 30 Days 
 
Characteristics 
Any Arthritis 
n= 7654 
Unspecified Arthritis 
n= 6016 
Rheumatoid Arthritis 
n= 898 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
No Supplement Use 
Glucosamine Only 
Chondroitin Only 
Glucosamine and Chondroitin 
1.0 (referent) 
2.2 (1.6-3.1) 
0.7 (0.3-1.4) 
6.2 (1.5-26.3) 
 
0.32 
0.01 
0.02 
1.0 (referent) 
2.5 (1.7-3.7) 
0.5 (0.2-1.3) 
7.4 (1.0-56.8) 
 
0.29 
0.01 
0.07 
1.0 (referent) 
1.7 (0.5-5.8) 
-- 
-- 
 
0.43 
-- 
-- 
Sex     
    Women 
    Men 
 
1.0 (referent) 
0.9 (0.7-1.0) 
 
 
0.02 
 
1.0 (referent) 
1.0 (0.8-1.1) 
 
 
0.70 
 
1.0 (referent) 
0.9 (0.6-1.3) 
 
 
0.48 
Age 
    18-39 years old 
    40-55 years old 
    56-70 years old 
    71-84 years old 
    >85 years old 
 
1.0 (referent) 
1.1 (0.9-1.5) 
1.5 (1.1-1.9) 
1.0 (0.8-1.3) 
1.0 (0.7-1.4) 
 
 
0.79 
0.00 
0.10 
0.21 
 
1.0 (referent) 
1.1 (0.8-1.5) 
1.4 (1.0-1.9) 
0.9 (0.7-1.3) 
1.0 (0.7-1.5) 
 
 
0.72 
0.00 
0.06 
0.58 
 
1.0 (referent) 
1.8 (0.9-3.5) 
2.4 (1.2-4.5) 
1.3 (0.7-2.4) 
1.4 (0.6-3.4) 
 
 
0.30 
0.02 
0.36 
0.77 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
1.0 (referent) 
1.2 (1.0-1.4) 
0.9 (0.7-1.1) 
0.7 (0.5-0.9) 
1.0 (0.5-2.2) 
 
 
0.04 
0.69 
0.03 
0.83 
 
1.0 (referent) 
1.2 (0.9-1.4) 
0.7 (0.6-0.9) 
0.7 (0.5-1.1) 
1.2 (0.4-3.7) 
 
 
0.15 
0.11 
0.18 
0.57 
 
1.0 (referent) 
1.7 (1.1-2.8) 
1.9 (1.2-2.8) 
0.9 (0.2-3.9) 
1.9 (0.4-10.6) 
 
 
0.28 
0.09 
0.53 
0.68 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1.0 (referent) 
1.2 (1.0-1.5) 
1.8 (1.5-2.1) 
 
 
0.30 
<0.01 
 
1.0 (referent) 
1.2 (1.0-1.5) 
2.0 (1.7-2.3) 
 
 
0.06 
<0.01 
 
1.0 (referent) 
1.7 (1.1-2.7) 
1.7 (1.1-2.8) 
 
 
0.23 
0.19 
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Education 
    Did Not Complete  High School 
     GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or     
    Doctoral Degree 
 
1.0 (referent) 
1.1 (0.7-1.6) 
1.1 (0.9-1.3) 
1.1 (0.9-1.4) 
1.2 (0.9-1.6) 
1.0 (0.8-1.2) 
0.9 (0.7-1.2) 
 
 
0.84 
0.89 
0.60 
0.17 
0.43 
0.11 
 
1.0 (referent) 
1.0 (0.6-1.5) 
1.1 (0.9-1.4) 
1.1 (0.9-1.5) 
1.3 (1.0-1.8) 
0.9 (0.7-1.2) 
1.0 (0.8-1.3) 
 
 
0.62 
0.80 
0.39 
0.05 
0.15 
0.73 
 
1.0 (referent) 
0.7 (0.2-2.4) 
0.8 (0.4-1.5) 
0.6 (0.3-1.2) 
0.7 (0.3-1.5) 
1.1 (0.5-2.6) 
0.5 (0.2-1.0) 
 
 
0.96 
0.89 
0.35 
0.74 
0.14 
0.06 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
1.0 (referent) 
1.3 (1.1-1.6) 
1.1 (0.9-1.4) 
 
 
0.04 
0.63 
 
1.0 (referent) 
1.3 (1.1-1.6) 
1.1 (0.8-1.3) 
 
 
0.03 
0.50 
 
1.0 (referent) 
2.6 (1.5-4.7) 
0.8 (0.4-1.5) 
 
 
<0.01 
0.03 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
1.0 (referent) 
1.2 (0.9-1.4) 
1.3 (1.0-1.6) 
1.0 (1.0-1.6) 
 
 
0.70 
0.08 
0.13 
 
1.0 (referent) 
1.3 (1.0-1.7) 
1.5 (1.2-1.9) 
1.5 (1.1-1.9) 
 
 
0.95 
0.01 
0.11 
 
1.0 (referent) 
0.7 (0.4-1.2) 
0.9 (0.5-1.5) 
0.8 (0.5-1.4) 
 
 
0.21 
0.69 
0.92 
No Other Health Conditions 
Other Health Conditions  
1.0 (referent) 
1.4 (1.2-1.6) 
 
<0.01 
1.0 (referent) 
1.6 (1.4-1.9) 
 
<0.01 
1.0 (referent) 
1.4 (0.9-2.2) 
 
0.16 
No Energy Therapies  
Energy Therapies 
1.0 (referent) 
1.1 (0.8-1.4) 
 
0.53 
1.0 (referent) 
1.1 (0.8-1.5) 
 
0.48 
1.0 (referent) 
0.9 (0.4-2.3) 
 
0.91 
No Acupuncture 
Acupuncture 
1.0 (referent) 
1.3 (0.8-2.0) 
 
0.29 
1.0 (referent) 
1.4 (0.9-2.4) 
 
0.16 
1.0 (referent) 
0.5 (0.2-1.9) 
 
0.35 
No Mind-Body Therapies 
Mind-Body Therapies 
1.0 (referent) 
1.3 (1.0-1.8) 
 
0.06 
1.0 (referent) 
1.4 (1.1-2.0) 
 
0.02 
1.0 (referent) 
0.4 (0.2-0.9) 
 
0.03 
No Chiropractic/ Osteopathic Therapy 
Chiropractic/ Osteopathic Therapy 
1.0 (referent) 
1.3 (1.0-1.6) 
 
0.02 
1.0 (referent) 
1.3 (1.0-1.6) 
 
0.03 
1.0 (referent) 
1.3 (0.6-2.9) 
 
0.46 
*Estimates presented were found using a logistic regression. 
**Chondroitin only and glucosamine and chondroitin yielded a small sample size in rheumatoid arthritis therefore, could not be analyzed. 
 
MULTIVARIABLE ANALYSES 
 Table 11 presents adjusted odds ratios, 95% Confidence intervals (95% CI), and p-values 
for selected characteristics and self-reported 12 month improved health among persons with any 
arthritis, unspecified arthritis, and rheumatoid arthritis. After adjusting for age, education, energy 
therapies, and mind-body therapies, supplement use (glucosamine only, chondroitin only, and 
both glucosamine and chondroitin) was not associated with self-reported improved health among 
persons with any arthritis. After adjusting for sex, age, BMI, education, mind-body therapies, 
and chiropractic/osteopathic therapy, supplement use (glucosamine only, chondroitin only, and 
both glucosamine and chondroitin) was not associated with self-reported 12 month improved 
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health among persons with unspecified arthritis. After adjusting for mind-body and 
chiropractic/osteopathic therapies, supplement use (glucosamine only, chondroitin only, and both 
glucosamine and chondroitin) was not associated with self-reported 12 month improved health 
among persons with rheumatoid arthritis. 
Adjusted age, education, energy therapies, and mind-body therapies were characteristics 
that yielded statistically significant associations with self-reported past 12 month improved 
health among persons with any arthritis. When compared to persons 18 to 39 years old, persons 
71 to 84 years old were 0.4 times likely to report past 12 month improved health (adjusted OR= 
0.4; p= 0.04) and persons 85 years or older were 0.3 times likely to report past 12 month 
improved health (adjusted OR= 0.3; p= <0.01). When compared to persons that did not complete 
high school, persons with an associate’s degree were 1.3 times likely to report past 12 month 
improved health than persons that did not complete high school (adjusted OR= 1.3; p= 0.02). 
Persons that engaged in energy therapies one or more times within the 12 months prior to the 
administration of the survey were 1.5 times likely to report past 12 month improved health than 
persons that did not  (adjusted OR=1.5; p= <0.01). Persons that engaged in mind-body therapies 
one or more times within the 12 months prior to the administration of the survey were also 1.5 
times likely to report past 12 month improved health than persons that did not  (adjusted 
OR=1.5; p= <0.01). 
Adjusted sex, age, BMI, education, mind-body therapies, and chiropractic/osteopathic 
therapy were characteristics that yielded statistically significant associations with self-reported 
12 month improved health among persons with unspecified arthritis, as illustrated in Table 11. 
Men were 0.8 time likely to report past 12 month improved health than women (adjusted OR= 
0.8; p= 0.03). When compared to persons 18 to 39 years old, person 71 to 84 years old were 0.4 
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time likely to report past 12 month improved health (adjusted OR= 0.4; p= 0.03) and persons 85 
years and older were 0.3 time likely to report past 12 month improve health (adjusted OR= 0.3; 
p= <0.01). When compared to persons that did not complete high school, persons with a high 
school diploma were 0.9 times likely to report past 12 month improved health (adjusted OR= 
0.9; p= 0.02). Obese persons (BMI ≥ 30) were 1.3 times likely to report past 12 month improved 
health than person who were either underweight or normal weight (adjusted OR= 1.3; p= 0.02). 
Persons that engaged in energy therapies one or more times within the 12 months prior to the 
administration of the survey were 1.5 times likely to report past 12 month improved health than 
persons that did not  (adjusted OR=1.5; p= 0.01). Persons that engaged in mind-body therapies 
one or more times within the 12 months prior to the administration of the survey were also 1.6 
times likely to report past 12 month improved health than persons that did not  (adjusted 
OR=1.6; p= 0.02). 
 Adjusted mind-body and chiropractic/osteopathic therapies yielded statistically 
significant associations with self-reported 12 month improved health among persons with 
rheumatoid arthritis, as illustrated in Table 11. When compared to persons that did not use mind-
body therapies in the 12 months prior to administration of the survey, persons that did use mind-
body therapies were about two times likely to report improved health (adjusted OR= 1.9; p= 
0.05). Persons that saw a chiropractor or osteopathic practitioner one or more times within the 12 
months prior to taking the survey were 1.8 time likely to report improved health than persons 
that did not (adjusted OR= 1.8; p= 0.04). 
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Table 11: Adjusted Odds Ratio for Glucosamine Use Within the Past 12 Months and Reports of Improved Health when Compared 
to 12 Months Ago among Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012 
National Health Interview Survey (NHIS) 
Self-Reported Improved Health over a 12-Month Period 
 
Characteristics 
Any Arthritis 
n= 7654 
Unspecified Arthritis 
n= 6016 
Rheumatoid Arthritis 
n= 898 
  OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
No Supplement Use 
Glucosamine Only 
Chondroitin Only 
Glucosamine and Chondroitin 
1.0 (referent) 
1.1 (0.8-1.6) 
0.6 (0.2-1.3) 
0.9 (0.6-1.3) 
 
0.19 
0.31 
0.96 
1.0 (referent) 
1.0 (0.6-1.5) 
0.6 (0.2-1.8) 
0.9 (0.6-1.3) 
 
0.51 
0.45 
0.98 
1.0 (referent) 
1.2 (0.6-2.5) 
0.2 (0.0-2.2) 
1.2 (0.4-3.2) 
 
0.25 
0.18 
0.38 
Sex    
    Women 
    Men 
 
1.0 (referent) 
0.9 (0.7-1.0) 
 
 
0.06 
 
1.0 (referent) 
0.8 (0.7-1.0) 
 
 
0.03 
 
-- 
-- 
 
-- 
-- 
Age 
    18-39 years old 
    40-55 years old 
    56-70 years old 
    71-84 years old 
    >85 years old 
 
1.0 (referent) 
0.6 (0.4-0.7) 
0.5 (0.4-0.7) 
0.4 (0.3-0.6) 
0.3 (0.2-0.4) 
 
 
0.15 
0.40 
0.04 
<0.01 
 
1.0 (referent) 
0.5 (0.4-0.7) 
0.5 (0.4-0.7) 
0.4 (0.3-0.6) 
0.3 (0.1-0.4) 
 
 
0.40 
0.45 
0.03 
<0.01 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
-- 
-- 
-- 
 
 
-- 
-- 
 
1.0 (referent) 
1.1 (0.9-1.4) 
1.3 (1.0-1.6) 
 
 
0.89 
0.02 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
Education 
    Did Not Complete  High School 
     GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or Doctoral Degree 
 
1.0 (referent) 
0.8 (0.5-1.3) 
0.9 (0.7-1.2) 
1.2 (0.9-1.6) 
1.3 (1.0-1.7) 
1.1 (0.8-1.5) 
1.2 (0.9-1.6) 
 
 
0.14 
0.06 
0.14 
0.02 
0.55 
0.21 
 
1.0 (referent) 
0.9 (0.5-1.6) 
0.9 (0.6-1.2) 
1.3 (0.9-1.8) 
1.3 (1.0-1.9) 
1.1 (0.8-1.6) 
1.3 (0.9-1.7) 
 
 
0.42 
0.02 
0.06 
0.08 
0.82 
0.21 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
1.0 (referent) 
1.0 (0.8-1.3) 
1.0 (0.8-1.2) 
1.1 (0.9-1.4) 
 
 
0.88 
0.32 
0.13 
 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
No Other Health Conditions 
Other Health Conditions  
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
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No Energy Therapies  
Energy Therapies 
1.0 (referent) 
1.5 (1.1-1.9) 
 
<0.01 
1.0 (referent) 
1.5 (1.1-2.0) 
 
0.01 
1.0 (referent) 
1.8 (0.9-3.4) 
 
0.07 
No Acupuncture 
Acupuncture 
1.0 (referent) 
1.4 (0.9-2.0) 
 
0.13 
1.0 (referent) 
1.4 (0.9-2.2) 
 
0.14 
1.0 (referent) 
2.3 (1.0-5.3) 
 
0.06 
No Mind-Body Therapies 
Mind-Body Therapies 
1.0 (referent) 
1.5 (1.1-2.1) 
 
<0.01 
1.0 (referent) 
1.6 (1.1-2.3) 
 
0.02 
1.0 (referent) 
1.9 (1.0-3.8) 
 
0.05 
No Chiropractic/ Osteopathic Therapy 
Chiropractic/ Osteopathic Therapy 
1.0 (referent) 
1.2 (0.9-2.0) 
 
0.12 
1.0 (referent) 
1.1 (0.9-1.5) 
 
0.29 
1.0 (referent) 
1.8 (1.0-3.1) 
 
0.04 
*Multivariable logistic regression models used to present the adjusted odds ratios, 95% Confidence Intervals (CI) and p-values. 
**Variables denoted by ‘—‘ were not included in the arthritis specific model. 
 
 
 Table 12 presents adjusted odds ratios, 95% Confidence intervals (95% CI), and p-values 
for selected characteristics and self-reported joint pain, aching, and stiffness within the past 30 
days prior to taking the survey among persons with any arthritis, unspecified arthritis, and 
rheumatoid arthritis. After adjusting for sex, age, race, BMI, poverty level, other health 
conditions, and other CAM therapies (acupuncture, energy, mind-body, and chiropractic/ 
osteopathic therapies), the use of chondroitin only one or more times during the past 30 days 
prior to taking the survey was found to be associated with self-reported past 30 day joint pain, 
aching, and stiffness among persons with any arthritis (adjusted OR= 0.6; p= <0.01). 
Glucosamine and chondroitin was also found to be associated with self-reported past 30 day joint 
pain, aching, and stiffness among persons with any arthritis (adjusted OR= 5.7; p= 0.03). 
Glucosamine only was not associated with past 30 day joint pain, aching, and stiffness among 
persons with any arthritis (adjusted OR= 2.1; p= 0.26), as can be seen in Table 12. After 
adjusting for age, BMI, poverty level, region, other health conditions, and other CAM therapies 
(acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), use of chondroitin 
only was found to be associated with past 30 day joint pain, aching, and stiffness among persons 
with unspecified arthritis (adjusted OR= 0.5; p= 0.02). Glucosamine only and glucosamine and 
chondroitin were not associated with past 30 day joint pain, aching, and stiffness among persons 
with unspecified arthritis (p> 0.05). After adjusting for poverty level and other CAM therapies 
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(acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), glucosamine only was 
also not associated with past 30 day joint pain, aching, and stiffness among persons with 
rheumatoid arthritis (p>0.05), as can be seen in Table 12. 
Adjusted sex, BMI, poverty level, other health conditions, and chiropractic/ osteopathic 
therapy were characteristics that yielded statistically significant associations with self-reported 
past 30 day joint pain, aching, and stiffness among persons with any arthritis. Men were 0.8 
times likely to report past 30 day joint pain, aching, and stiffness than women (adjusted OR= 0.8; 
p= 0.02). Obese persons (BMI≥ 30) 1.6 times likely to report past 30 day joint pain, aching, and 
stiffness than persons that were either underweight or normal weight (BMI< 25) (adjusted OR= 
1.6; p= <0.01). When compared to person above the poverty line, person below the poverty line 
were 1.4 time more likely to report past 30 day joint pain, aching, and stiffness (adjusted OR= 
1.4; p= 0.03). Persons with other health conditions were 1.3 time likely to report past 30 day 
joint pain, aching, and stiffness than persons without these conditions (adjusted OR= 1.3; p= 
<0.01). Persons that saw a chiropractor or osteopathic practitioner one or more times within the 
12 months prior to taking the survey were 1.2 times likely to report past 30 day joint pain, 
aching, and stiffness than persons that did not (adjusted OR= 1.2; p= 0.05). 
Adjusted age, BMI, poverty level, region, other health conditions, chiropractic/ 
osteopathic therapy, and mind-body therapy were characteristics that yielded statistically 
significant associations with self-reported past 30 day joint pain, aching, and stiffness among 
persons with unspecified arthritis. When compared to persons 18 to 39 years old, persons 56 to 
70 years old were 1.3 times likely to report past 30 day joint pain, aching, and stiffness (adjusted 
OR= 1.4; p= 0.01). Obese persons (BMI≥ 30) were 1.8 times likely to report past 30 day joint 
pain, aching, and stiffness than persons that were either underweight or normal weight (BMI< 
50 
 
25) (adjusted OR= 1.8; p= <0.01). Persons with unknown poverty level were 1.8 times likely to 
report past 30 day joint pain, aching, and stiffness than persons below poverty level (adjusted 
OR= 1.8; p= <0.01). Persons in the South were 1.6 times likely to report past 30 day joint pain, 
aching, and stiffness than persons in the Northeast region of the U.S (adjusted OR= 1.6; p= 
<0.01). Persons with other health conditions were 1.5 times likely to report past 30 day joint 
pain, aching, and stiffness than persons without other health conditions (adjusted OR= 1.5; p= 
<0.01). Persons that engaged in mind-body therapies one or more times within the 12 months 
prior to the administration of the survey were also 1.4 times likely to report past 30 day joint 
pain, aching, and stiffness than persons that did not  (adjusted OR=1.4; p= 0.04). Persons that 
saw a chiropractor or osteopathic practitioner one or more times within the 12 months prior to 
taking the survey were 1.3 times likely to report past 30 day joint pain, aching, and stiffness than 
persons that did not (adjusted OR= 1.3; p= 0.04). 
Adjusted poverty level, chiropractic/osteopathic therapy, and mind-body therapy were 
characteristics that yielded statistically significant associations with self-reported past 30 day 
joint pain, aching, and stiffness among persons with rheumatoid arthritis. When compared to 
persons above poverty level, persons below poverty level were 2.6 time likely to report past 30 
day joint pain, aching, and stiffness (adjusted OR= 2.6; p= <0.01) and persons with unknown 
poverty level were 0.8 times likely to report past 30 day joint pain, aching, and stiffness 
(adjusted OR= 0.8; p= 0.05). Persons that saw a chiropractor or osteopathic practitioner one or 
more times within the 12 months prior to taking the survey were two times likely to report past 
30 day joint pain, aching, and stiffness than persons that did not (adjusted OR= 2.0; p= 0.01). 
Persons that engaged in mind-body therapies one or more times within the 12 months prior to the 
51 
 
administration of the survey were also 1.4 times likely to report past 30 day joint pain, aching, 
and stiffness than persons that did not  (adjusted OR=1.4; p= 0.02).  
 
Table 12: Adjusted Odds Ratio for Glucosamine and/or Chondroitin Use within the Past 30 days and Reports of Joint Pain, Aching, or Stiffness 
in or around a Joint over the Past 30 Days among Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 
2012 National Health Interview Survey (NHIS) 
Self-Reported Joint Pain in Past 30 Days 
 
Characteristics 
Any Arthritis 
n= 7654 
Unspecified Arthritis 
n= 6016 
Rheumatoid Arthritis 
n= 898 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
No Supplement Use 
Glucosamine Only 
Chondroitin Only 
Glucosamine and Chondroitin 
1.0(referent) 
2.1 (1.5-3.0) 
0.6 (0.3-1.2) 
5.7 (1.3-24.3) 
 
0.26 
<0.01 
0.03 
1.0 (referent) 
2.5 (1.7-3.6) 
0.5 (0.2-1.1) 
6.7 (0.2-1.1) 
 
0.22 
<0.01 
0.08 
1.0 (referent) 
0.8 (0.3-2.0) 
-- 
-- 
 
0.57 
-- 
-- 
Sex     
    Women 
    Men 
 
1.0 (referent) 
0.8 (0.7-1.0) 
 
 
0.02 
 
-- 
-- 
 
-- 
-- 
 
-- 
-- 
 
-- 
-- 
Age 
    18-39 years old 
    40-55 years old 
    56-70 years old 
    71-84 years old 
    >85 years old 
 
1.0 (referent) 
1.1 (0.8-1.4) 
1.4 (1.1-1.8) 
1.0 (0.7-1.3) 
1.0 (0.7-1.5) 
 
 
0.69 
<0.01 
0.10 
0.72 
 
1.0 (referent) 
1.1 (0.8-1.5) 
1.3 (1.0-1.8) 
1.0 (0.7-1.4) 
1.2 (0.8-1.8) 
 
 
0.94 
0.01 
0.09 
0.60 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
Race/Ethnicity 
     White 
     Black/African American 
     Hispanic/Latino 
     American Indian or Alaskan Native 
     Asian 
 
1.0 (referent) 
1.1 (0.9-1.3) 
0.8 (0.7-1.0) 
0.7 (0.5-1.0) 
0.9 (0.4-2.0) 
 
 
0.13 
0.53 
0.20 
0.98 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
BMI Category 
    ≤ 24.9 
    >24.9 and <30.0 
    ≥ 30.0 
 
1.0 (referent) 
1.2 (1.0-1.5) 
1.6 (1.4-2.0) 
 
 
0.57 
<0.01 
 
1.0 (referent) 
1.2 (1.0-1.4) 
1.8 (1.5-2.2) 
 
 
0.09 
<0.01 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
Education 
    Did Not Complete  High School 
     GED 
    High School Diploma 
    Some College, No Degree 
    Associate’s Degree 
    Bachelor's Degree 
    Master's, Professional, or     
    Doctoral Degree 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
Poverty Level 
    Above Poverty Line 
    Below Poverty Line 
    Unknown 
 
1.0 (referent) 
1.4 (1.1-1.7) 
1.1 (0.9-1.4) 
 
 
0.03 
0.64 
 
1.0 (referent) 
1.2 (1.0-1.4) 
1.8 (1.5-2.2) 
 
 
0.09 
<0.01 
 
1.0 (referent) 
2.6 (1.5-4.7) 
0.8 (0.4-1.6) 
 
 
<0.01 
0.05 
Region 
    Northeast 
    Midwest 
    South 
    West 
 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
 
1.0 (referent) 
1.3 (1.0-1.7) 
1.6 (1.2-2.0) 
1.5 (1.1-1.9) 
 
 
0.88 
<0.01 
0.13 
 
-- 
-- 
-- 
-- 
 
-- 
-- 
-- 
-- 
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No Other Health Conditions 
Other Health Conditions  
1.0 (referent) 
1.3 (1.1-1.5) 
 
<0.01 
1.0 (referent) 
1.5 (1.3-1.8) 
 
<0.01 
-- 
-- 
-- 
-- 
No Energy Therapies  
Energy Therapies 
1.0 (referent) 
1.0 (0.8-1.4) 
 
0.78 
1.0 (referent) 
1.1 (0.8-1.5) 
 
0.58 
1.0 (referent) 
1.3 (0.6-2.6) 
 
0.47 
No Acupuncture 
Acupuncture 
1.0 (referent) 
1.2 (1.0-1.8) 
 
0.51 
1.0 (referent) 
1.3 (0.8-2.2) 
 
0.27 
1.0 (referent) 
0.5 (0.2-1.2) 
 
0.12 
No Mind-Body Therapies 
Mind-Body Therapies 
1.0 (referent) 
1.2 (0.9-1.6) 
 
0.18 
1.0 (referent) 
1.4 (1.0-2.0) 
 
0.04 
1.0 (referent) 
0.4 (0.2-0.8) 
 
0.02 
No Chiropractic/ Osteopathic Therapy 
Chiropractic/ Osteopathic Therapy 
1.0 (referent) 
1.2 (0.7-1.8) 
 
0.05 
1.0 (referent) 
1.3 (1.0-1.6) 
 
0.04 
1.0 (referent) 
2.0 (1.2-3.4) 
 
0.01 
*Multivariable logistic regression models used to present adjusted odds ratios, 95% Confidence Intervals (CI) and p-values. 
**Chondroitin only and glucosamine and chondroitin yielded a small sample size in rheumatoid arthritis therefore, could not be analyzed. This is   
Denoted by ‘—‘. 
***Other variable denoted by ‘--‘ were not included in the arthritis specific model. 
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CHAPTER V 
DISCUSSION & CONCLUSION 
DISCUSSION 
This study set out to identify the socio-demographic characteristics of U.S. adults with 
any arthritis, unspecified arthritis, and rheumatoid arthritis, identify their use of glucosamine 
and/or chondroitin, and  to determine if reports of improved health or reports of joint pain, 
aching, and stiffness differs based on glucosamine and/or chondroitin use. In 2012, 
approximately 21.8% of U.S adults had any arthritis, 17.0% had unspecified arthritis, and 2.5% 
had rheumatoid arthritis. This thesis found that women were more likely than men to report some 
form of arthritis. This was expected because gender, particularly being a woman, has been 
identified as a risk factor for arthritis (Johnson & Hunter 2014; Turkiewicz et al. 2014). The 
prevalence of any arthritis, unspecified arthritis, and rheumatoid arthritis increases with age and 
BMI. Both of these characteristics were previously identified as risk factors for arthritis (Johnson 
& Hunter 2014). In addition, persons with diabetes and/or heart conditions (other health 
conditions) had prevalence rates of some form of arthritis more than twice of that of persons who 
did not have other health conditions. A previous study similarly found large proportions of 
persons with arthritis to have comorbidities such as diabetes and heart disease (Barbour et al. 
2013).   
When assessing past 12 month supplement use among persons with any arthritis, 
approximately 3.7% used glucosamine, 0.4% used chondroitin, and 3.4% used both glucosamine 
and chondroitin. When assessing past 30 day supplement use among persons with any arthritis, 
approximately 5.1% of persons with any arthritis used glucosamine, 0.6% used chondroitin, and 
0.4% used both glucosamine and chondroitin. Approximately 3.7% of persons with unspecified 
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arthritis reported past 12 month glucosamine use, 0.5% reported past 12 month chondroitin use, 
and 3.8% reported past 12 month both glucosamine and chondroitin use. Approximately 5.5% of 
persons with unspecified arthritis had past 30 day use of glucosamine, 0.5% had past 30 day use 
of chondroitin, and 0.4% had past 30 day use of both glucosamine and chondroitin. 
Approximately 2.4% of persons with rheumatoid arthritis used glucosamine while 0.3% used 
chondroitin, and 2.1% used both glucosamine and chondroitin within the past 12 months. 
Approximately 2.9% of persons with rheumatoid arthritis had past 30 day use of glucosamine 
while 0.7% used chondroitin, and 0.5% used both glucosamine and chondroitin. 
Women used more of all supplements (past 12 months and past 30 days) except past 12 
month use of chondroitin among persons with any arthritis. Among persons with unspecified 
arthritis, women were more likely than men to report past 12 month glucosamine and past 12 
month both glucosamine and chondroitin use. Men, however, were more likely to be chondroitin 
users (57.3%). Among persons with rheumatoid arthritis, the majority of glucosamine and both 
glucosamine and chondroitin users were women (59.3% and 58.0% respectively) however; men 
made up 94.0% of chondroitin use. 
Persons 56 to 70 years old had the highest proportion of past 12 month and 30 day 
supplement use among persons with unspecified arthritis. Among persons with unspecified 
arthritis, persons 40-55 years old made up 85.1% of 12 month chondroitin use. Persons age 56 to 
70 years old with unspecified arthritis reported the highest proportion of past 30 day supplement 
use (57.9% glucosamine, 57.1% chondroitin, 33.0% both glucosamine and chondroitin). Persons 
56 to 70 years old reported the largest proportion of past 30 day glucosamine use (42.9%) and 
chondroitin use (85.8%) among persons with rheumatoid arthritis. A previous study identified 
persons 50 to 59 years of age as having the highest prevalence of CAM use (Barnes et al. 2008). 
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While part of the 50 to 59 and the 56 to 70 age groups overlap, it was unexpected to find that 
persons 18 to 39 years old reported the largest proportion of past 30 day use of both glucosamine 
and chondroitin among persons with rheumatoid arthritis.  
White people accounted for the majority of all past 30 day supplement use among 
persons with any arthritis. Past 30 day supplement use was most common among white persons 
with unspecified arthritis (90.9% glucosamine, 78.3% chondroitin, and 67.2% both glucosamine 
and chondroitin).  Persons in the Northeast had the lowest prevalence of any past 12 month and 
past 30 day supplement use among persons with any arthritis. Persons in the West accounted for 
a large proportion of past 12 month glucosamine use while a large proportion of chondroitin use 
was in the Midwest among persons with any arthritis. The Northeast also had the lowest 
proportion of any past 30 day supplement use among persons with unspecified arthritis. Among 
persons with unspecified arthritis, more than half (54.9%) of past 12 month chondroitin use were 
from persons in the Midwest. Similarly, a large proportion of persons with rheumatoid arthritis 
that reported past 30 day chondroitin use were from the Midwest (60.9%). These findings are 
somewhat similar to the results of a Canadian study. This study found that glucosamine use 
occurred more in the western regions when compared to all other regions (Hopman et al. 2006). 
Obese (BMI ≥ 30.0) individuals had the highest proportion of past 12 month glucosamine 
and chondroitin use (42.9% and 94.0% respectively) among persons with unspecified arthritis. 
Similarly, obese (BMI ≥ 30.0) individuals had the highest proportion of past 12 month 
glucosamine and chondroitin use (42.9% and 94.0% respectively) among persons with 
rheumatoid arthritis. These findings were surprising to find. In a study observing CAM use 
among overweight and obese persons with radiographic knee osteoarthritis, BMI was inversely 
associated with CAM use. Persons classified as obese (BMI ≥ 30) were less likely to use CAM 
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therapies, alone or in combination with conventional medications when compared to persons 
underweight or normal weight (BMI < 25) (Lapane et al. 2013).   
Persons above the poverty line had the highest proportion of supplement use among 
persons with any arthritis. Persons above poverty level also had the highest proportion of all past 
30 day supplement use (93.0% glucosamine, 76.6% chondroitin, and 95.5% both glucosamine 
and chondroitin) among persons with unspecified arthritis. Past 12 month glucosamine use and 
past 12 month both glucosamine and chondroitin use were most common among persons above 
poverty level (83.3% and 100.0% respectively) with rheumatoid arthritis. These findings 
coincides with the Australian study of persons 45 years of age and older that found that higher 
income is associated with glucosamine use (Sibbritt et al. 2012). However, persons below 
poverty level made up the highest proportion of past 12 month chondroitin use (85.1%) among 
persons with rheumatoid arthritis.  
MAJOR FINDINGS  
Past 12 month use of glucosamine only was not associated with reported past 12 month 
improved health among persons with any arthritis (adjusted OR=1.1; p= 0.19), unspecified 
arthritis (adjusted OR= 1.0; p= 0.51), or rheumatoid arthritis (adjusted OR=1.2; p= 0.25). Past 30 
day use of glucosamine only was also not associated with reports of past 30 day joint pain, 
aching, and stiffness among persons with any arthritis (adjusted OR= 2.1; p= 0.26), unspecified 
arthritis (adjusted OR= 2.5; p= 0.22), or rheumatoid arthritis (adjusted OR= 0.8; p= 0.57). Past 
12 month use of chondroitin only was not associated with reports of past 12 month improved 
health among persons with any arthritis (adjusted OR= 0.6; p= 0.31), unspecified arthritis 
(adjusted OR= 0.6; p= 0.45), or rheumatoid arthritis (adjusted OR= 0.2; p= 0.18). Past 30 day 
use of chondroitin only was associated with reported past 30 day joint pain, aching, and stiffness 
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among persons with any arthritis (adjusted OR= 0.6; p= <0.01) and unspecified arthritis 
(adjusted OR= 0.5; p= <0.01). Past 12 month use of both glucosamine and chondroitin was not 
associated with reports of past 12 month improved health among persons with any arthritis 
(adjusted OR= 0.9; p= 0.96), unspecified arthritis (adjusted OR= 0.9; p= 0.98), or rheumatoid 
arthritis (adjusted OR= 1.2; p= 0.38). Past 30 day use of both glucosamine and chondroitin was 
associated with reports of past 30 day joint pain, aching, and stiffness among persons with any 
arthritis (adjusted OR= 5.7; p= 0.03) but was not associated with joint pain, aching, and stiffness 
among persons with unspecified arthritis (adjusted OR= 6.7; p= 0.08). 
 There were no observable associations between past 12 month use of glucosamine and/or 
chondroitin and reports of improved health among persons with any arthritis, unspecified 
arthritis, or rheumatoid arthritis. These findings support the claims from clinical studies 
presented by Kwoh and Clegg (Kwoh et al. 2014; Clegg et al. 2006). This thesis finds no 
evidence to support the marketed claim that glucosamine and/or chondroitin can improve the 
health conditions of persons with arthritis. 
 The association of past 30 day use of chondroitin only and reports of past 30 day joint 
pain, aching, and stiffness among persons with any arthritis and unspecified arthritis yielded a 
decreased odds. This suggests that persons with past 30 day use of chondroitin were less likely to 
report joint pain, aching, and stiffness than persons that did not use the observed supplements. 
Several factors could have contributed to these findings. To start, only a small proportion of the 
observed subpopulations were users of chondroitin only. In addition, when compared to 
glucosamine and combination (glucosamine and chondroitin) supplements, chondroitin seems to 
be less readily available on the market. Finally, this finding may also suggest that the use of 
chondroitin alone can be for reasons other than those associated with arthritis. 
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Past 30 day use of both glucosamine and chondroitin was also found to be associated 
with self-reported past 30 day joint pain, aching, and stiffness among persons with any arthritis. 
This finding would suggest that persons who use glucosamine and chondroitin within the 30 days 
prior to administration of the survey were more likely to report past 30 day joint pain, aching, 
and stiffness. This could also be interpreted to mean that persons that experience joint pain are 
more likely to use chondroitin and glucosamine. This may mean that marketing glucosamine and 
chondroitin together as a CAM treatment for persons with arthritis has been effective. 
Glucosamine and/or chondroitin are marketed to persons with arthritis for their potential 
chondroprotective properties (Gibson et al. 2014).  These findings may be used to provide insight 
on the effectiveness of marketing. It is important to note that glucosamine and/or chondroitin are 
classified as dietary supplements therefore, are not regulated drugs. Marketing claims may not be 
backed by scientific findings. 
IMPORTANCE 
While there are several clinical studies examining the effects of glucosamine and/or 
chondroitin on arthritic and rheumatoid condition and outcomes, there are very few observational 
studies that do the same. To date, there are no observational studies that have specifically 
investigated the relationship between self-reported glucosamine and/or chondroitin use among 
persons with some form of arthritis and reports of improved health or self-reported pain. While 
this study was limited to the data provided in the 2012 NHIS adult sample, it fills in the literature 
gap by providing observational analyses of these associations among persons with any arthritis, 
unspecified arthritis, and rheumatoid arthritis with reports of improved health and joint pain, 
aching, or stiffness. 
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LIMITATIONS 
Although 2012 NHIS data included variables specifically for some arthritis and 
rheumatoid conditions (i.e. rheumatoid arthritis, gout, lupus, and fibromyalgia), there was not a 
variable specifically for osteoarthritis. Previous clinical studies examined the effect of 
glucosamine use on osteoarthritis specifically (Bruyere & Reginster 2007; McAlindon et al. 
2000; Jawahar et al. 2012); however, this cross-sectional observational study could not 
investigate this relationship with the given data. Perhaps if future observational studies examine 
this specific relationship, results would be different.  
In addition, the exposure and outcome measurements for this study left room for 
uncertainty. The question “Compared with 12 months ago, would you say your health is better, worse, 
or about the same?” covers a large time frame. Various factors can affect a response to this 
question and though the study was focused on persons with arthritis, a response to this question 
could be unrelated. Likewise, the question “Please tell me which of these supplements you have 
taken during the past 12 months?” covers a large time frame. Taking a supplement one or more 
time may not be a good estimate to analyze.  
The following questions are better measures in term of time frame: “Which of these 
supplements have you taken during the past 30 days?” and “During the past 30 days, have you had 
any symptoms of pain, aching, or stiffness in or around a joint?” However, they fall short of determining 
an association with symptom improvement. Asking about joint pain is not the same as asking if joint pain 
has decreased or been eliminated. Better measures to analyze this were not included in 2012 NHIS. 
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FUTURE STUDIES 
 As previously mentioned, an analysis of the association of glucosamine and/or 
chondroitin use among persons specifically with osteoarthritis and improved health could not be 
analyzed. Future observational studies should examine this relationship as well as glucosamine 
and/or chondroitin’s relationship with decreased joint pain among persons with specific forms of 
arthritis. Perhaps, NHIS could include an “osteoarthritis” variable in future surveys. Finally, 
while the findings of this study did not yield any statistically significant association between 
glucosamine and/or chondroitin use and reports of improved health, future studies are needed 
that can examine these relationships longitudinally through experimental study designs.  
CONCLUSION 
 Past 12 month use of glucosamine and/or chondroitin is not associated with self-reported 
12 month improved health among persons with any arthritis, unspecified arthritis, or rheumatoid 
arthritis. Past 30 day glucosamine use was not associated with reports of past 30 day pain, 
aching, and stiffness among person with any arthritis, unspecified arthritis, and rheumatoid 
arthritis however, past 30 day use of chondroitin only and past 30 day use of both glucosamine 
and chondroitin is associated with reports of past 30 day pain, aching, and stiffness among 
person with any arthritis. Past 30 day use of chondroitin only is also associated with past 30 day 
pain, aching, and stiffness among person with unspecified arthritis. Because marketing is 
expected to have an effect on the factors found to be associated, this study warrants the need for 
future studies on the effects of advertisement and supplement use. 
 
 
61 
 
REFERENCES 
 
1. Baker JF, Billig E, Michaud K, Ibrahim S, Caplan L, Cannon GW, and et al. ( 2015). 
Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis. Arthritis 
Rheumatology 
2. Barbour KE, Helmick CG, Theis KA, Murphy LB, Hootman JM, Brady TJ, Cheng YJ. 
Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation-
United States, 2010-2012. MMWR 2013; 62 (44):869-873. 
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004). Complementary and 
alternative medicine use among adults: United States, 2002. Natl Health Stat Report. 
2(2): 54-71. 
4. Barnes PM, Bloom B, Nahin RL (2008). Complementary and alternative medicine use 
among adults and children: United States, 2007. Natl Health Stat Report. (12):1-23. 
5. Bernatsky S, Dekis A, Hudson M, Pineau C, Boire G, Fortin P, and et al. (2014). 
Rheumatoid arthritis prevalence in Quebec. BMC Research Notes. 7: 937. 
6. Barsky AJ et al. (2010). A randomized trial of three psychosocial treatments for the 
symptoms of rheumatoid arthritis. Semin Arthritis Rheum., 40(3): 222-32. 
7. Bruyere O & Reginster JY. (2007). Glucosamine and chondroitin sulfate as therapeutic 
agents for knee and hip osteoarthritis. Drugs Aging. 24(7):573-80. 
8. Centers for Disease Control and Prevention. 2014. Arthritis: Meeting the Challenge of 
Living Well at A Glance (2014). Retrieved from: 
http://www.cdc.gov/chronicdisease/resources/publications/AAG/arthritis.htm 
9. Centers for Disease Control, Prevention. CDC (2007). National and state medical 
expenditures and lost earnings attributable to arthritis and other rheumatic conditions—
United States, 2003. MMWR Morb Mortal Wkly Rep, 56: 4–7. 
10. Choy EHS & Panayi GS (2001). Cytokinepathways and Joint Inflammation in 
Rheumatoid Arthritis. N Engl J Med, Vol. 344 (12):907-916. 
11. Clegg DO, Reda DJ, Harris CL, et al. (2006). Glucosamine, chondroitin sulfate, and the 
two in combination for painful knee osteoarthritis. N Engl J Med; 354: 795-808. 
12. Corbett MS et al. (2013). Acupuncture and other physical treatments for the relief of pain 
due to osteoarthritis of the knee: network meta-analysis. Osteoarthritis and Cartilage, 
21(9): 1290–1298. 
13. Dahmer S & Schiller RM (2008). Glucosamine. American Family Physician, 78(4):471-
476. 
14. Elders MJ et al. (2000). The increasing impact of arthritis on public health. J Rheumatol 
Suppl 60:6–8. 
15. Gabriel SE et al. (2001) The epidemiology of rheumatoid arthritis. Rheum Dis Clin North 
Am. 27(2):269–81. 
16. Gibson M et al. (2014). Intra-articular delivery of glucosamine for treatment of 
experimental osteoarthritis created by a medial meniscectomy in a rat model. J Orthop 
Res. 32(2):302-9. 
17. Haaz S & Bartlett SJ (2011). Yoga for Arthritis: A Scoping Review.  Rheum Dis Clin 
North Am. 37(1):33-46. 
18. Helmick CG, Felson DT, Lawrence RC, et al. (2008). For the National Arthritis Data 
Workshop. Estimates of the prevalence of arthritis and other rheumatic conditions in the 
United States. Part I. Arthritis Rheum 58: 15-25. 
62 
 
19. Henrotin et al. (2013). Physiological effects of oral glucosamine on joint health: current 
status and consensus on future research priorities. BMC Research Notes 6:115 
20. Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004). Use of complementary 
therapies among primary care clinic patients with arthritis. Preventing Chronic Diseases, 
1(4):A12. 
21. Hopman WM, Towheed TE, Gao Y, Berger C, Joseph L, et al. (2006) Prevalence of and 
factors associated with glucosamine use in Canada. Osteoarthritis Cartilage 14: 1288–
1293. 
22. Hunziker EB. (2002). Articular cartilage repair: basic science and clinical progress. A 
review of the current status and prospects. Osteoarthritis Cartilage 10:432–463. 
23. Institutional Review Board Policies and Procedures For Faculty, Staff, and Student 
Researchers. (n.d.). Georgia State University. Retrieved on May 19, 2015 from 
http://ursa.research.gsu.edu/files/2013/10/IRB-Manual.pdf. 
24. Jawahar R, Yang S, Eaton CB, McAlindon T, Lapane KL. (2012). Gender-specific 
correlates of complementary and alternative medicine use for knee osteoarthritis.  J 
Womens Health (Larchmt). 21(10):1091-9. 
25. Jiang Y, Shi X, Tang Y (2015). Efficacy and safety of acupuncture therapy for nerve 
deafness: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 8(2):2614-
20. 
26. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, Woodard J, et al. (2007). 
Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in 
African Americans and Caucasians: the Johnston County Osteoarthritis Project. 
J Rheumatol, 34: 172–180. 
27. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, Woodard J, et al. (2009). 
Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in 
African Americans and Caucasians: the Johnston County Osteoarthritis Project, 
J Rheumatol, 36: 809–815. 
28. Johnson VL & Hunter DJ (2014). The epidemiology of osteoarthritis. Best Practice & 
Research Clinical Rheumatology 28: 5–15 
29. Kaptchuk TJ & Eisenberg DM. (2001). Varieties of healing. 2: a taxonomy of 
unconventional healing practices. Ann Intern Med. 135(3):196-204. 
30. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. (2005). 
Recent Trends in Use of Herbal and Other Natural Products. Arch Intern Med. 
165(3):281-286.  
31. Kwoh CK, Roemer FW, Hannon MJ, Moore CE, Jakicic JM, Guermazi A, Green SM, 
Evans RW, Boudreau R. (2014). Effect of oral glucosamine on joint structure in 
individuals with chronic knee pain: a randomized, placebo-controlled clinical trial. 
Arthritis Rheumatol. 66(4):930-9. 
32. Lapane et al. (2013). CAM use among overweight and obese persons with radiographic 
knee osteoarthritis. BMC Complement Altern Med., 13: 241 
33. Lawrence RC, Felson DT, Helmick CG, Arnold LM, et al. (2008). Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part 2. 
Arthritis Rheum 58: 26-35. 
34. McAlindon TE, LaValley MP, Gulin JP, Felson DT. (2000). Glucosamine and 
chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-
analysis. JAMA 283(11):1469-75. 
63 
 
35. Md Yusof MY & Emery P (2013) Targeting Interleukin-6 in Rheumatoid Arthritis. 
Drugs, 73:341–356. 
36. Mollenhauer JA. (2008). Perspectives on articular cartilage biology and osteoarthritis. 
Injury 39:S5–S12. 
37. Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. 
(2010). Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, 
Minnesota, 1955-2007. Arthritis and Rheumatism, 62(6), 1576–1582.  
38. NCCIH (National Center for Complementary and Integrative Health), formerly known as 
NCCAM (National Center for Complementary and Alternative Medicine) (2000). 
Expanding Horizons of Healthcare: Five-Year Strategic Plan 2001-2005. Washington 
DC: U.S. Department of Health and Human Services; NIH Publication No. 01-5001. 
39. Simon RR, Marks V, Leeds AR, Anderson JW (2011). A comprehensive review of oral 
glucosamine use and effects on glucose metabolism in normal and diabetic individuals. 
Diabetes Metab Res Rev. 27(1): 14–27.  
40. Smolen JS & Steiner G (2003). Therapeutic Strategies for Rheumatoid Arthritis. Nature 
Review, Drug Discovery, 2:473-488. 
41. Sibbritt D, Adams J, Lui CW, Broom A, Wardle J. (2012). Who uses glucosamine and 
why? A study of 266,848 Australians aged 45 years and older. PLoS One.; 7(7): e41540.  
42. Stuber K, Sajko S, Kristmanson K (2011). Efficacy of glucosamine, chondroitin, and 
methylsulfonylmethane for spinal degenerative joint disease and degenerative disc 
disease: a systematic review. J Can Chiropr Assoc, 55(1): 47-55. 
43. Thorman P, Dixner A, Sundberg T (2010). Effects of Chiropractic Care on Pain and 
Function in Patients with Hip Osteoarthritis Waiting for Arthroplasty: a Clinical Pilot 
Trial. Journal of Manipulative and Physiological Therapeutics, 33(6): 438-444. 
44. Timbo BB, Ross MP, McCarthy PV, & Lin CTJ (2006). Dietary supplements in a 
national survey: prevalence of use and reports of adverse events. Journal of the American 
Dietetic Association, 106(12), 1966-1974. 
45. Turkiewicz A, Petersson LF, Björk J, Hawker G, Dahlberg LE, Lohmander LS et al. 
(2014). Current and future impact of osteoarthritis on health care: a population-based 
study with projections to year 2032. Osteoarthiris and Cartilage. 22:1826-1832. 
46. Visser et al. (2002). How to Diagnose Rheumatoid Arthritis Early: A Prediction Model 
for Persistent (Erosive) Arthritis. Arthritis and Rheumatism, 46(2): 357-365. 
47. Waljee J, Zhong L, Baser O, Yuce H, Fox DA, Chung KC (2015). The Incidence of 
Upper and Lower Extremity Surgery for Rheumatoid Arthritis Among Medicare 
Beneficiaries. The Journal of Bone & Joint Surgery. 97 (5) 403-410 
48. Wang C et al. (2009). Tai Chi is effective in treating knee osteoarthritis: a randomized 
controlled trial. Arthritis Rheum., 61(11): 1545-53. 
49. Wu D, Huang Y, Gu Y, Fan W. (2013). Efficacies if different preparations of 
glucosamine for the treatment of osteoarthritis: a meta-analysis if randomized, double-
blind, placebo-controlled trials. Int J Clin Pract.67(6): 585-594. 
 
